[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3508
1. Patel S, Liu D, Caron P, Seiter K: Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine. Leuk Lymphoma; 2007 May;48(5):1032-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Camptothecin / analogs & derivatives. Intestinal Neoplasms / drug therapy. Intestine, Small / pathology. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Prognosis. Recurrence. Remission Induction

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487750.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


2. Konuma T, Tomonari A, Takahashi S, Ooi J, Tsukada N, Yamada T, Sato H, Nagayama H, Iseki T, Tojo A, Asano S: Early-onset thyrotoxicosis after unrelated cord blood transplantation for acute myelogenous leukemia. Int J Hematol; 2006 May;83(4):348-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-onset thyrotoxicosis after unrelated cord blood transplantation for acute myelogenous leukemia.
  • Patient 1 is a 32-year-old woman with acute myelogenous leukemia (AML)-M5a who underwent CBT.
  • Patient 2 is a 42-year-old man with AML-M4 who underwent CBT.
  • [MeSH-major] Autoimmune Diseases / blood. Cord Blood Stem Cell Transplantation. Leukemia, Myeloid, Acute. Thyrotoxicosis / blood
  • [MeSH-minor] Adult. Autoantibodies / blood. Autoantibodies / immunology. Female. Humans. Iodide Peroxidase / immunology. Male. Remission, Spontaneous. Thyroxine / blood. Thyroxine / immunology. Transplantation, Homologous. Triiodothyronine / blood. Triiodothyronine / immunology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1997 Aug;98(2):453-7 [9266950.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jan;74(1):3-5 [1727826.001]
  • [Cites] Transplantation. 2001 Feb 15;71(3):406-11 [11233902.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Nov;89(11):5810-4 [15531546.001]
  • [Cites] Br J Haematol. 1993 Dec;85(4):778-82 [7918043.001]
  • [Cites] Transplantation. 1987 Sep;44(3):463-4 [3307069.001]
  • [Cites] Bone Marrow Transplant. 2000 Dec;26(12):1347-9 [11223977.001]
  • [Cites] Bone Marrow Transplant. 1990 Jul;6(1):49-51 [2390632.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):660-3 [11736951.001]
  • [Cites] Bone Marrow Transplant. 1995 Jan;15(1):71-6 [7742758.001]
  • [Cites] Br J Haematol. 1990 Jan;74(1):118-9 [2310693.001]
  • [Cites] N Engl J Med. 1985 Feb 28;312(9):546-52 [3881675.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):2965-71 [12843128.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3813-20 [15280199.001]
  • [Cites] Blood. 2004 Jan 15;103(2):489-91 [12933570.001]
  • [Cites] Bone Marrow Transplant. 1992 Oct;10(4):397-8 [1422500.001]
  • (PMID = 16757437.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Autoantibodies; 06LU7C9H1V / Triiodothyronine; EC 1.11.1.8 / Iodide Peroxidase; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


3. Ullah K, Raza S, Ahmed P, Chaudhry QU, Satti TM, Ahmed S, Mirza SH, Akhtar F, Kamal K, Akhtar FM: Post-transplant infections: single center experience from the developing world. Int J Infect Dis; 2008 Mar;12(2):203-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From July 2001 to September 2006, patients with malignant and non-malignant hematological disorders having human leukocyte antigen (HLA)-matched sibling donors were selected for transplant.
  • Indications for transplant included aplastic anemia (n=66), beta-thalassemia major (n=40), chronic myeloid leukemia (n=33), acute leukemia (n=8), and miscellaneous disorders (n=7).
  • [MeSH-minor] Adolescent. Adult. Anti-Inflammatory Agents / administration & dosage. Child. Child, Preschool. Developed Countries. Female. Fungi / isolation & purification. Graft vs Host Disease / prevention & control. Gram-Negative Bacteria / isolation & purification. Hospitals, Military. Humans. Immunosuppressive Agents / administration & dosage. Infant. Male. Middle Aged. Pakistan / epidemiology. Proportional Hazards Models. Siblings. Survival Analysis. Transplantation, Homologous / adverse effects. Transplantation, Homologous / methods. Viruses / isolation & purification

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17920999.001).
  • [ISSN] 1201-9712
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


Advertisement
4. Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, van Putten WJ, Kayser S, Verdonck LF, Lübbert M, Ossenkoppele GJ, Germing U, Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganser A, Döhner H, Löwenberg B, Döhner K, Delwel R: High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol; 2010 Apr 20;28(12):2101-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
  • PURPOSE The purpose of this study was to investigate frequency and prognostic significance of high EVI1 expression in acute myeloid leukemia (AML).
  • PATIENTS AND METHODS A diagnostic assay detecting multiple EVI1 splice variants was developed to determine the relative EVI1 expression by single real-time quantitative polymerase chain reaction in 1,382 newly diagnosed adult patients with AML younger than 60 years.
  • Patients were treated on four Dutch-Belgian HOVON (n = 458) and two German-Austrian AML Study Group protocols (n = 924).
  • This adverse prognostic impact was more pronounced in the intermediate cytogenetic risk group (EFS; HR, 1.64; P < .001; and RFS; HR, 1.55; P = .02), and was also apparent in cytogenetically normal AML (EFS; HR, 1.67; P = .008).
  • EVI1(+) was virtually absent in favorable-risk AML and AML with NPM1 mutations.
  • Patients with EVI1(+) AML (n = 28) who received allogeneic stem cell transplantation in first CR had significantly better 5-year RFS (33% +/- 10% v 0%).
  • CONCLUSION EVI1 expression in AML is unequally distributed in cytogenetic subtypes.
  • It predicts poor outcome, particularly among intermediate cytogenetic risk AML.
  • Patients with EVI1(+) AML may benefit from allogeneic transplantation in first CR.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 7. DNA-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Monosomy. Proto-Oncogenes / genetics. Transcription Factors / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Cytogenetic Analysis. Disease-Free Survival. Europe. Female. Gene Expression Regulation, Neoplastic. Genetic Predisposition to Disease. Humans. Kaplan-Meier Estimate. Logistic Models. Male. Middle Aged. Odds Ratio. Polymerase Chain Reaction. Proportional Hazards Models. Recurrence. Retrospective Studies. Risk Assessment. Risk Factors. Stem Cell Transplantation. Time Factors. Transplantation, Homologous. Treatment Outcome. Up-Regulation. Young Adult

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20308656.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MECOM protein, human; 0 / Transcription Factors
  •  go-up   go-down


5. Rossi D, Deambrogi C, Capello D, Cerri M, Lunghi M, Parvis G, Saglio G, Gaidano G, Cilloni D: JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders. Br J Haematol; 2006 Oct;135(2):267-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Leukemia, Myeloid / genetics. Myeloproliferative Disorders / genetics. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Cell Transformation, Neoplastic / genetics. Female. Humans. Janus Kinase 2. Male. Middle Aged. Philadelphia Chromosome

  • Genetic Alliance. consumer health - Chronic Myeloproliferative Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16956348.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


6. Das PK, Warkentin DI, Hewko R, Forrest DL: Serotonin syndrome after concomitant treatment with linezolid and meperidine. Clin Infect Dis; 2008 Jan 15;46(2):264-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe serotonin syndrome after concomitant use of linezolid and meperidine in a 27-year-old man with acute leukemia.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Interactions. Drug Therapy, Combination. Humans. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / drug therapy. Linezolid. Male

  • Genetic Alliance. consumer health - Serotonin Syndrome.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827857114 for PMID:18171260 [PharmGKB] .
  • Hazardous Substances Data Bank. LINEZOLID .
  • Hazardous Substances Data Bank. MEPERIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18171260.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetamides; 0 / Oxazolidinones; 9E338QE28F / Meperidine; ISQ9I6J12J / Linezolid
  •  go-up   go-down


7. Morerio C, Acquila M, Rosanda C, Rapella A, Tassano E, Micalizzi C, Panarello C: t(9;11)(p22;p15) with NUP98-LEDGF fusion gene in pediatric acute myeloid leukemia. Leuk Res; 2005 Apr;29(4):467-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] t(9;11)(p22;p15) with NUP98-LEDGF fusion gene in pediatric acute myeloid leukemia.
  • The rare t(9;11)(p22;p15) translocation is associated with adult acute myeloid leukemia (AML) with immature forms.
  • We report a novel fusion of the NUP98 and LEDGF genes in a pediatric AML with intermediate characteristics between M2-M3 French-American-British (FAB) subtypes exhibiting the same chromosomal rearrangement.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 22. Intercellular Signaling Peptides and Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Nuclear Pore Complex Proteins / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725483.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Nuclear Pore Complex Proteins; 0 / Nup98 protein, human; 0 / lens epithelium-derived growth factor
  •  go-up   go-down


8. Saliba RM, Komanduri KV, Giralt S, de Souza J, Patah P, Oran B, Couriel D, Rondon G, Champlin RE, de Lima M: Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant; 2009 May;43(9):685-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML.
  • Lymphocyte and platelet recovery may influence outcomes of allo-SCT for treatment of AML.
  • We studied 106 AML patients treated with fludarabine and melphalan reduced-intensity conditioning and allo-SCT.
  • [MeSH-major] Hematopoiesis. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Platelets / physiology. Female. Graft Survival. Humans. Kinetics. Lymphocytes / physiology. Male. Melphalan / therapeutic use. Middle Aged. Transplantation Conditioning / methods. Transplantation, Homologous. Tumor Burden. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Aug 15;106(4):1154-63 [15870183.001]
  • [Cites] Blood. 1998 May 1;91(9):3481-6 [9558408.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1688-95 [16131570.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Apr;13(4):454-62 [17382251.001]
  • [Cites] Bone Marrow Transplant. 2007 May;39(10):613-22 [17384658.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4543-51 [17671230.001]
  • [Cites] Leukemia. 2008 Feb;22(2):258-64 [17989720.001]
  • [Cites] Br J Haematol. 2001 Jan;112(1):219-27 [11167808.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3380-9 [11369627.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2326-31 [11588026.001]
  • [Cites] Bone Marrow Transplant. 2001 Nov;28(10):951-6 [11753550.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3690-7 [12393402.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(1):23-30 [12815474.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1865-70 [12970788.001]
  • [Cites] Blood. 2003 Oct 15;102(8):3052-9 [12842990.001]
  • [Cites] Bone Marrow Transplant. 2004 Feb;33(4):419-23 [14688814.001]
  • [Cites] Br J Haematol. 2004 Apr;125(2):217-24 [15059145.001]
  • [Cites] Blood. 2004 Aug 1;104(3):865-72 [15090449.001]
  • [Cites] Blood. 1993 Sep 1;82(5):1672-8 [8395913.001]
  • [Cites] Bone Marrow Transplant. 1996 Aug;18(2):339-45 [8864444.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1608-16 [9193360.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(1):101-8 [16258533.001]
  • (PMID = 19011667.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA055164; United States / NCI NIH HHS / CA / R01 CA109326
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ NIHMS588906; NLM/ PMC4038152
  •  go-up   go-down


9. Han JY, Cheon JH, Kim DH, Chon HJ, Kim SK, Kim TI, Min YH, Kim WH: [Ileal mucormycosis diagnosed by colonoscopy in a patient with acute myeloid leukemia]. Korean J Gastroenterol; 2008 Sep;52(3):179-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ileal mucormycosis diagnosed by colonoscopy in a patient with acute myeloid leukemia].
  • [MeSH-major] Ileal Diseases / diagnosis. Leukemia, Myeloid, Acute / complications. Mucormycosis / diagnosis
  • [MeSH-minor] Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Colonoscopy. Humans. Ileum / pathology. Immunocompromised Host. Male. Tomography, X-Ray Computed. Young Adult


10. Bao L, Wang X, Ryder J, Ji M, Chen Y, Chen H, Sun H, Yang Y, Du X, Kerzic P, Gross SA, Yao L, Lv L, Fu H, Lin G, Irons RD: Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: subtypes, cytogenetic features and FLT3 mutations. Eur J Haematol; 2006 Jul;77(1):35-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: subtypes, cytogenetic features and FLT3 mutations.
  • We report a prospective study of 174 unselected adult de novo acute myeloid leukemia (AML) cases diagnosed using the WHO classification.
  • Of those, 57 (33%) were AML with recurrent cytogenetic abnormalities, 41 were (24%) AML with multilineage dysplasia, 74 (42%) were AML not otherwise categorized, and two were acute leukemias of ambiguous lineage.
  • Clonal cytogenetic abnormalities were detected in 64% of the WHO AML cases with t(15;17) (15%), t(8;21) (12%), +8 (11%), -7/del7q (8%) and del9q (5%) being the most common ones.
  • The FLT3/ITD mutations (FMS-like tyrosine kinase 3/internal tandem duplication) were observed in 12% of the WHO AML cases, which is much lower than ones in the literature, while the 6% incidence of the FLT3-activating loop mutations (either FLT3/D835 or FLT3/I836) was comparable with others.
  • [MeSH-major] Leukemia, Myeloid, Acute / classification. Leukemia, Myeloid, Acute / genetics. Mutation. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Classification. Cytogenetic Analysis. Female. Humans. Leukocytosis / genetics. Male. Middle Aged. Prospective Studies. World Health Organization

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16573742.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


11. Knapper S, Mills KI, Gilkes AF, Austin SJ, Walsh V, Burnett AK: The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood; 2006 Nov 15;108(10):3494-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.
  • The receptor tyrosine kinase FLT3 is a promising molecular therapeutic target in acute myeloid leukemia (AML).
  • We studied the effects of lestaurtinib (CEP701) and PKC412, 2 small molecule inhibitors of FLT3, on 65 diagnostic AML blast samples.
  • [MeSH-major] Carbazoles / pharmacology. Indoles / pharmacology. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / pathology. Staurosporine / analogs & derivatives
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Apoptosis / drug effects. Blast Crisis / pathology. Drug Screening Assays, Antitumor. Female. Humans. Male. Middle Aged. Mutation. Protein Kinase C / antagonists & inhibitors. Protein-Tyrosine Kinases / antagonists & inhibitors. Signal Transduction. Tumor Cells, Cultured. fms-Like Tyrosine Kinase 3 / genetics. fms-Like Tyrosine Kinase 3 / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16868253.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbazoles; 0 / Indoles; 120685-11-2 / 4'-N-benzoylstaurosporine; DO989GC5D1 / lestaurtinib; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 2.7.11.13 / Protein Kinase C; H88EPA0A3N / Staurosporine
  •  go-up   go-down


12. Wu HX, Qian SX, Hong M, Zhang YP, Lu H, Zhang R, Zhang XY, Chen LJ, Lu RN, Zhang SJ, Liu P, Ge Z, Fan L, Wang L, Xu J, Tian T, Zhu Y, Qiu HX, Xu W, Sheng RL, Li JY: [Allogeneic peripheral blood stem cell transplantation for 75 cases of hematologic malignancies]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec;16(6):1330-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 75 patients included 35 patients with chronic myeloid leukemia (CML), 30 patients with acute myeloid leukemia, 5 patients with severe aplastic anemia, 3 patients with acute lymphocytic leukemia, one patients with multiple myeloma and one patients with paroxysmal nocturnal hemoglobinuria.
  • Among 29 dead patients, 9 died of disease relapse, 7 died of III-IV grade of acute GVHD and 7 died of severe infection (2 patients developed interstitial pneumonia).

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099638.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Warman M, Lahav J, Feldberg E, Halperin D: Invasive tracheal aspergillosis treated successfully with voriconazole: clinical report and review of the literature. Ann Otol Rhinol Laryngol; 2007 Oct;116(10):713-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this report we describe a young patient with acute myeloid leukemia who was affected by invasive tracheal aspergillosis.
  • [MeSH-minor] Adult. Aspergillus flavus / isolation & purification. Fatal Outcome. Female. Humans. Laryngoscopy. Leukemia, Myeloid, Acute / complications. Voriconazole

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17987775.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; JFU09I87TR / Voriconazole
  •  go-up   go-down


14. Preiss BS, Bergmann OJ, Friis LS, Sørensen AG, Frederiksen M, Gadeberg OV, Mourits-Andersen T, Oestergaard B, Kerndrup GB, AML Study Group of Southern Denmark: Cytogenetic findings in adult secondary acute myeloid leukemia (AML): frequency of favorable and adverse chromosomal aberrations do not differ from adult de novo AML. Cancer Genet Cytogenet; 2010 Oct 15;202(2):108-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic findings in adult secondary acute myeloid leukemia (AML): frequency of favorable and adverse chromosomal aberrations do not differ from adult de novo AML.
  • During a 15-year period, 161 adult patients were diagnosed with secondary acute myeloid leukemia (s-AML) in the region of Southern Denmark.
  • In 73 patients, the AML diagnosis was preceded by myelodysplastic syndrome (MDS-AML), in 31 patients by an antecedent hematologic disease, and in 57 patients by treatment with chemotherapy and/or irradiation (t-AML).
  • MDS-AML correlated to a normal karyotype (P < 0.001).
  • t-AML correlated to abnormal clones with numerical and structural aberrations (P = 0.03), five or more unrelated aberrations (P = 0.03), marker chromosomes (P = 0.006), abnormal mitoses only (P = 0.01), female sex (P < 0.001), and -7 (P = 0.006).
  • The frequencies of aberrations in s-AML patients were compared with an age-matched group of de novo AML patients diagnosed in the same area and period.
  • In this comparison, s-AML only correlated to -7 (P = 0.02).
  • In 42 patients, we found that MDS patients with an abnormal karyotype were more likely to show cytogenetic evolution during progression to AML than MDS patients with a normal karyotype (P = 0.01).
  • We conclude that population-based cytogenetic studies of adult s-AML and age- and sex-matched de novo AML show comparable distributions of chromosome abnormalities.
  • [MeSH-major] Chromosome Aberrations. Cytogenetic Analysis. Leukemia, Myeloid, Acute / genetics. Neoplasms, Second Primary / genetics
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Chromosome Breakage. Chromosomes, Human / genetics. Denmark / epidemiology. Humans. Incidence. Karyotyping. Middle Aged. Neoplasm Recurrence, Local / genetics. Ploidies. Young Adult


15. Kakkar N, Das S, Joseph JM: Pseudo Chediak Higashi inclusions in a patient with acute myeloblastic leukemia. Indian J Cancer; 2010 Jan-Mar;47(1):81-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudo Chediak Higashi inclusions in a patient with acute myeloblastic leukemia.
  • [MeSH-major] Inclusion Bodies / pathology. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Female. Humans. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071802.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


16. Jeeninga RE, Jan B, van der Linden B, van den Berg H, Berkhout B: Construction of a minimal HIV-1 variant that selectively replicates in leukemic derived T-cell lines: towards a new virotherapy approach. Cancer Res; 2005 Apr 15;65(8):3347-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • T-cell acute lymphoblastic leukemia is a high-risk type of blood-cell cancer.
  • We analyzed the possibility of developing virotherapy for T-cell acute lymphoblastic leukemia.
  • The mini-HIV variant that uses CD4 and CXCR4 for cell entry could potentially be used against CXCR4-expressing malignancies such as T-lymphoblastic leukemia/lymphoma, natural killer leukemia, and some myeloid leukemias.
  • [MeSH-major] HIV-1 / physiology. Leukemia-Lymphoma, Adult T-Cell / therapy. Leukemia-Lymphoma, Adult T-Cell / virology. T-Lymphocytes / virology

  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Women and HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15833868.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R21-AI47017-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Receptors, CXCR4
  •  go-up   go-down


17. Feusner J, Gregory JJ Jr: Update on the management of pediatric acute promyelocytic leukemia. Clin Adv Hematol Oncol; 2006 Nov;4(11):854-5; author reply 855-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the management of pediatric acute promyelocytic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Component Transfusion. Leukemia, Promyelocytic, Acute / therapy
  • [MeSH-minor] Adult. Child. Child, Preschool. Female. Hemorrhage / blood. Hemorrhage / etiology. Hemorrhage / mortality. Hemorrhage / therapy. Humans. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Adv Hematol Oncol. 2006 Apr;4(4):263-5 [16728936.001]
  • (PMID = 17193721.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


18. Stock W: Clinical trials in adult AML. Clin Adv Hematol Oncol; 2009 Jun;7(6):8-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trials in adult AML.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Drugs, Investigational / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Double-Blind Method. Hematopoietic Stem Cell Transplantation. Humans. Middle Aged. Multicenter Studies as Topic. Randomized Controlled Trials as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645130.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Investigational
  • [Number-of-references] 30
  •  go-up   go-down


19. Jourdan E, Rigal-Huguet F, Marit G, Vey N, Dastugue N, Fegueux N, Molina L, Gastaut JA, Legros L, Zerazhi H, Cailleres S, Bauduer F, Bordessoule D, Attal M, Blaise D, Pigneux A, BGMT Study Group: One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission. Br J Haematol; 2005 May;129(3):403-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
  • We report on a randomized trial aimed to determine the impact of a second consolidative high-dose cytarabine-based chemotherapy (HiDAC) in patients with acute myeloid leukaemia prior to an autologous stem cell transplantation (ASCT).
  • Overall survival, leukaemia-free survival and cumulative incidence of relapse and non-relapse deaths were 41% and 53% (P = 0.14), 39% and 48% (P = 0.12), 57% and 47% (P = 0.11), 8% and 8% (P = 0.95) for HiDAC 1 and HiDAC 2 groups, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Daunorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Multivariate Analysis. Recurrence. Remission Induction. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842665.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


20. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR: Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood; 2010 Sep 30;116(13):2224-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience.
  • Monosomal karyotype (MK), defined as 2 or more monosomies, or a single monosomy in the presence of structural abnormalities, has recently been reported as identifying a distinct subset of acute myeloid leukemia (AML) patients with an extremely poor prognosis.
  • In an effort to confirm this observation, we analyzed the prognostic impact of MK in 1344 AML patients between the ages of 16 and 88 years treated on Southwest Oncology Group protocols.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Monosomy
  • [MeSH-minor] Adult. Age Factors. Aged. Chromosome Aberrations. Cytogenetic Analysis. Female. Humans. Kaplan-Meier Estimate. Karyotyping. Male. Middle Aged. Prognosis


21. Liu YR, Wang YZ, Chen SS, Chang Y, Fu JY, Li LD, Wang H, Yu H, Jiang B, Huang XJ: [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2007 Nov;28(11):731-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
  • OBJECTIVE: To analyze the immunophenotype and leukemia associated immunophenotype (LAIP) of leukemia cells from patients with acute myeloid leukemia (AML) in minimal residual disease (MRD) detection.
  • METHODS: Four-color multiparametric flow cytometry (FCM) with CD45/SSC gating was used to determine the expression of the following antibodies of CD7, CD117, CD33, CD34, CD10, CD19, CD56, CD38, CD13, CD14, CD64, CD9, CD16, CD2, CD5, CD11b, CD123, HLA-DR in 610 AML patients and 20 normal bone marrow (NBM) samples.
  • In AML patients, most cases were CD117+ (95.08%), CD38+ (94.74%), CD9+ (84.93%), CD33+ (84.60%), HLA-DR+ (77.23%) and CD13 (75.25%).
  • 86.39% of AML patients were found to have at least one LAIP, the highest incidence being in AML-M1 and M3 subtypes and the lowest in AML-M4Eo subtype.
  • For asynchronous antigen expression, CD34+ CD64+, CD117+ CD11b+ , CD34+ CD38(-/dim) and CD34+ HLA-DR(-/dim) were seldom expressed on normal BMMNCs (about 0.01%), and the logarithm difference between AML and NBM was larger than 3.0, being the more sensitive LAIP.
  • CONCLUSION: MRD detection by multiparameter flow cytometry can be applied to more than 80% of AML patients.
  • [MeSH-major] Immunophenotyping. Leukemia, Myeloid, Acute / immunology. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Adult. Female. Flow Cytometry / methods. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457262.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


22. Basa J, Wolska-Smoleń T, Walter Z, Skotnicki AB: [Granulocytic sarcoma with late transformation into acute myeloblastic leukemia--case report]. Przegl Lek; 2006;63(8):706-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granulocytic sarcoma with late transformation into acute myeloblastic leukemia--case report].
  • Case presentation of a 28-year-old patient with acute myeloblastic leukemia (FAB AML-M4), who underwent surgery of an inguinal tumor a year before the diagnosis of leukemia was made.
  • In retrospective assessment a diagnosis of granulocytic sarcoma was made.
  • [MeSH-major] Brain Neoplasms / secondary. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / etiology. Sarcoma, Myeloid / complications. Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Cell Transformation, Neoplastic / pathology. Disease-Free Survival. Fatal Outcome. Groin. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Remission Induction / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17441389.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


23. Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Döhner H, Döhner K, German-Austrian AML Study Group: Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood; 2009 May 7;113(19):4505-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.
  • To evaluate the incidence and clinical impact of WT1 gene mutations in younger adult patients with cytogenetically normal acute myeloid leukemia (CN-AML), sequencing of the complete coding region was performed in diagnostic samples from 617 patients who were treated on 3 German-Austrian AML Study Group protocols.
  • In conclusion, in our large cohort of younger adults with CN-AML, WT1 mutation as a single molecular marker did not impact on outcome.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Mutation / genetics. WT1 Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Austria. Biomarkers, Tumor / genetics. Cohort Studies. Cytogenetic Analysis. Female. Germany. Humans. Male. Middle Aged. Prognosis. Survival Rate. Tandem Repeat Sequences / genetics. Young Adult. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19221039.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / WT1 Proteins; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


24. Farag SS, Bolwell BJ, Elder PJ, Kalaycio M, Lin T, Pohlman B, Penza S, Marcucci G, Blum W, Sobecks R, Avalos BR, Byrd JC, Copelan E: High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia. Bone Marrow Transplant; 2005 Apr;35(7):653-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.
  • SUMMARY: To reduce relapse following allogeneic transplantation for AML, intensification of high-dose busulfan/cyclophosphamide using additional agents has been investigated but with few reported comparisons.
  • We compared an intensified regimen of etoposide (60 mg/kg), busulphan (14 mg/kg), and cyclophosphamide (120 mg/kg) (BuCyVP) with BuCy2 in 237 AML patients.
  • Overall, our results do not support the use of the more intensive BuCyVP regimen over BuCy2 in either early or more advanced disease AML patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Busulfan / administration & dosage. Cause of Death. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Female. Graft vs Host Disease. Humans. Male. Middle Aged. Survival Analysis. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711571.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


25. Bao T, Smith BD, Karp JE: New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation. Clin Adv Hematol Oncol; 2005 Apr;3(4):287-96, 302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation.
  • Acute myeloid leukemia continues to present formidable treatment challenges as there is not yet a "standard approach" that reliably and safely cures the majority of adults with this disorder.
  • Efforts to better understand the basic cellular and molecular biology of acute myeloid leukemia have unveiled a complicated network of signaling pathways that support the cancer cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Leukemia, Myeloid / drug therapy. Neoplasm Proteins / antagonists & inhibitors. Signal Transduction / drug effects
  • [MeSH-minor] Acute Disease. Adult. Aged. Angiogenesis Inhibitors / pharmacology. Angiogenesis Inhibitors / therapeutic use. Clinical Trials as Topic. Drug Delivery Systems. Farnesyltranstransferase / antagonists & inhibitors. Forecasting. Humans. MAP Kinase Signaling System / drug effects. Middle Aged. Multicenter Studies as Topic. Neovascularization, Pathologic / drug therapy. Protein Kinase Inhibitors / pharmacology. Protein Kinase Inhibitors / therapeutic use. Protein Kinases / physiology. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / physiology. fms-Like Tyrosine Kinase 3 / antagonists & inhibitors. fms-Like Tyrosine Kinase 3 / physiology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167001.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / Protein Kinase Inhibitors; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.5.1.29 / Farnesyltranstransferase; EC 2.7.- / Protein Kinases; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Number-of-references] 106
  •  go-up   go-down


26. Van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G, Panzer-Grümayer ER, Schrappe M, Schrauder A, Meyer C, Marschalek R, Nigro LL, Metzler M, Basso G, Mann G, Den Boer ML, Biondi A, Pieters R, Van Dongen JJ, Interfant-99 Study Group: Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia; 2009 Jun;23(6):1073-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
  • Acute lymphoblastic leukemia (ALL) in infants younger than 1 year is a rare but relatively homogeneous disease ( approximately 80% MLL gene rearranged, approximately 70% CD10-negative) when compared with childhood and adult ALL.
  • Several studies in children and adults with ALL have shown that minimal residual disease (MRD) status is a strong and independent prognostic factor.
  • [MeSH-major] Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Follow-Up Studies. Gene Rearrangement. Genes, Immunoglobulin. Histone-Lysine N-Methyltransferase. Humans. Infant. Infant, Newborn. Myeloid-Lymphoid Leukemia Protein / genetics. Polymerase Chain Reaction. Prognosis. Receptors, Antigen, T-Cell / genetics. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212338.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300130
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / Receptors, Antigen, T-Cell; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Investigator] Pieters R; de Rossi G; Biondi A; Suppiah R; Felice M; Mann G; Schrappe M; Janka-Schaub G; Stary J; Silverman L; Fester A; Mechinaud F; Li CK; Hovi L; Campbell M; Szczepañski T; Rubnitz JE; Hann I; Vora A
  •  go-up   go-down


27. Chevallier P, Al Nawakil C, Vigouroux S, Talmant P, Harousseau JL, Garand R: Two cases of acute lymphoblastic leukaemia following acute myeloid leukaemia. Leuk Res; 2008 Jun;32(6):1001-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of acute lymphoblastic leukaemia following acute myeloid leukaemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Monocytic, Acute / complications. Leukemia, Myelomonocytic, Acute / complications. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / chemically induced
  • [MeSH-minor] Acute Disease. Adult. Fatal Outcome. Female. Flow Cytometry. Humans. Immunophenotyping. Male. Middle Aged. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18093650.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


28. Mori H, Sakai H, Sanada M, Shimamoto K, Sasaki S, Azuma R, Higuchi T, Harada H, Niikura H, Omine M, Fujita K, Takahashi N: [Clinical analysis of HLA-DR-negative non-M3 AML]. Rinsho Ketsueki; 2007 Jul;48(7):547-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of HLA-DR-negative non-M3 AML].
  • The type of leukemia was defined as HLA-DR(-) non-M3-AML, when HLA antigens were detected by flow cytometry at an incidence of < 20% of the blast population excluding M3-AML.
  • Out of 109 patients with de novo acute myeloid leukemia, 8 patients had HLA-DR(-) non-AML-M3.
  • Overall survival and disease-free survival showed no significant differences between the HLA-DR(-) non- M3-AML group and the HLA-DR(+) AML group.
  • [MeSH-major] HLA-DR Antigens / analysis. Leukemia, Myeloid, Acute / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Flow Cytometry. Humans. Leukemia, Promyelocytic, Acute / immunology. Leukemia, Promyelocytic, Acute / mortality. Male. Middle Aged. Remission Induction

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695303.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / HLA-DR Antigens
  •  go-up   go-down


29. Portugal RD, Garnica M, Nucci M: Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol; 2009 Aug 10;27(23):3849-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We tested the D-index in 11 patients with acute myeloid leukemia (AML) who developed IMI during neutropenia and 33 AML patients without IMI (controls).
  • [MeSH-minor] Adolescent. Adult. Area Under Curve. Female. Humans. Leukemia, Myeloid, Acute / drug therapy. Leukocyte Count. Male. Mathematical Computing. Middle Aged. Patient Selection. Predictive Value of Tests. ROC Curve. Risk Assessment / methods. Risk Factors. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597026.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


30. Creutzig U, Büchner T, Sauerland MC, Zimmermann M, Reinhardt D, Döhner H, Schlenk RF: Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer; 2008 Feb 1;112(3):562-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
  • BACKGROUND: Data on the impact of age in acute myeloid leukemia (AML) patients <30 years treated in pediatric and adult trials are scarce.
  • METHODS: In all, 891 patients <18 years were treated in the pediatric trials AML-BFM 93/98 and 290 adolescents and young adults (>16 to <30 years) in the AMLCG 92/99 and AMLSG HD93/98A trials.
  • RESULTS: Initial features and risk factors differed considerably between infants (<2 years) and older age groups and only slightly between children (2 to <13), adolescents (13 to <21) and young adults (21 to <30).
  • Treatment results were most favorable in children (5-year event free survival [EFS]: 54% +/- 3%), slightly inferior in adolescents (46% +/- 4%, P = .03), and unfavorable in young adults (28% +/- 5%, P = .0001).
  • Excluding patients with favorable karyotypes, the results were similar in infants and children (EFS: 44% +/- 4% and 46% +/- 3%, respectively) and inferior in adolescents (35% +/- 4%) and young adults (23% +/- 4%).
  • EFS was especially poor in young adults, with blasts >5%.
  • When comparing the same age groups, outcome was similar between the trial groups, which differed from reports concerning acute lymphoblastic leukemia.
  • [MeSH-major] Aging / physiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / physiopathology
  • [MeSH-minor] Adolescent. Adult. Blast Crisis / pathology. Bone Marrow / pathology. Child. Child, Preschool. Clinical Trials as Topic. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Idarubicin / administration & dosage. Infant. Infant, Newborn. Male. Prognosis. Risk Factors. Survival Analysis. Treatment Outcome


31. Buyck HC, Holliman R, Else J, O'Regan L, Willis F, Grubnic S, Marsh J, Chakrabarti S: An unusual cause of acute abdomen following allogeneic transplantation: a zoonotic disease revisited. Bone Marrow Transplant; 2008 Jun;41(12):1069-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual cause of acute abdomen following allogeneic transplantation: a zoonotic disease revisited.
  • [MeSH-major] Abdomen, Acute / microbiology. Hematopoietic Stem Cell Transplantation / adverse effects. Mycobacterium bovis / isolation & purification. Peritonitis, Tuberculous / diagnosis
  • [MeSH-minor] Adult. Emigrants and Immigrants. Endemic Diseases. Female. Humans. Leukemia, Myeloid, Acute / therapy. Mexico / epidemiology. Mexico / ethnology. Transplantation Conditioning. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317455.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


32. Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade C, Attal M, Payrastre B, Demur C, Récher C: The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia; 2009 Jun;23(6):1029-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia.
  • The phosphoinositide 3-kinase/Akt pathway is an important signalling pathway governing cell survival and proliferation in acute myeloid leukaemia (AML).
  • As full activation of Akt requires phosphorylation on both threonine 308 (Thr308) and serine 473 (Ser473) residues, we studied the level of phosphorylation on the both sites in 58 AML samples by flow cytometry.
  • Neither screening for AKT1 E17K mutation nor changes in the level of PTEN expression and phosphorylation could be linked to increased phosphorylation on Thr308 in high-risk cytogenetic AML cells.
  • Moreover, the specific Akt inhibitor, Akti-1/2, inhibited cell proliferation and clonogenic properties, and induced apoptosis in AML cells with high-risk cytogenetics, suggesting that Akt may represent a therapeutic target in high-risk AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Proto-Oncogene Proteins c-akt / metabolism
  • [MeSH-minor] Adolescent. Adult. Apoptosis. Cell Proliferation. Cytogenetic Analysis. Female. Humans. Male. Middle Aged. Phosphorylation. Prognosis. Protein Phosphatase 2 / metabolism. Risk Assessment. Serine / metabolism. Survival Rate. Threonine / metabolism. Young Adult


33. La Starza R, Brandimarte L, Pierini V, Nofrini V, Gorello P, Crescenzi B, Berchicci L, Matteucci C, Romoli S, Beacci D, Rosati R, Martelli MF, Mecucci C: A NUP98-positive acute myeloid leukemia with a t(11;12)(p15;q13) without HOXC cluster gene involvement. Cancer Genet Cytogenet; 2009 Sep;193(2):109-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A NUP98-positive acute myeloid leukemia with a t(11;12)(p15;q13) without HOXC cluster gene involvement.
  • We report a case of adult acute myeloid leukemia with a new t(11;12)(p15;q13) underlying a NUP98 rearrangement without HOXC cluster gene involvement.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 12. Genes, Homeobox. Leukemia, Myeloid, Acute / genetics. Nuclear Pore Complex Proteins / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Female. Humans. In Situ Hybridization, Fluorescence. Multigene Family

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19665072.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Pore Complex Proteins; 0 / Nup98 protein, human
  •  go-up   go-down


34. Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S, Astolfi A, Chiaretti S, Vitale A, Messa F, Impera L, Baldazzi C, D'Addabbo P, Papayannidis C, Lonoce A, Colarossi S, Vignetti M, Piccaluga PP, Paolini S, Russo D, Pane F, Saglio G, Baccarani M, Foà R, Martinelli G: Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood; 2009 Sep 3;114(10):2159-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP).
  • The BCR-ABL1 fusion gene defines the subgroup of acute lymphoblastic leukemia (ALL) with the worst clinical prognosis.
  • To identify oncogenic lesions that combine with BCR-ABL1 to cause ALL, we used Affymetrix Genome-Wide Human SNP arrays (250K NspI and SNP 6.0), fluorescence in situ hybridization, and genomic polymerase chain reaction to study 106 cases of adult BCR-ABL1-positive ALL.
  • The IKZF1 deletion also was identified in the progression of chronic myeloid leukemia to lymphoid blast crisis (66%) but never in myeloid blast crisis or chronic-phase chronic myeloid leukemia or in patients with acute myeloid leukemia.
  • [MeSH-major] Base Sequence / genetics. Chromosomes, Human, Pair 7 / genetics. Fusion Proteins, bcr-abl / genetics. Ikaros Transcription Factor / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Sequence Deletion
  • [MeSH-minor] Adolescent. Adult. Aged. Blast Crisis / genetics. Blast Crisis / metabolism. Cell Line, Tumor. Codon, Initiator / genetics. Codon, Initiator / metabolism. Cohort Studies. Exons / genetics. Female. Gene Expression Regulation, Leukemic / genetics. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / metabolism. Male. Microarray Analysis. Middle Aged. Polymorphism, Single Nucleotide

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Blood. 2010 Sep 23;116(12):2196
  • (PMID = 19589926.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Initiator; 0 / IKZF1 protein, human; 148971-36-2 / Ikaros Transcription Factor; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


35. Kiyoi H, Naoe T: FLT3 mutations in acute myeloid leukemia. Methods Mol Med; 2006;125:189-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLT3 mutations in acute myeloid leukemia.
  • The prevalence of an internal tandem duplication (ITD) of the juxtamembrane domain-coding sequence and a missense mutation of D835 within the kinase domain of the FLT3 gene is 15-35% and 5-10% of adults with acute myeloid leukemia (AML), respectively.
  • Several large-scale studies in well-documented patients published to date have demonstrated that FLT3 mutations are strongly associated with a poor prognosis and a high leukemia cell count in patients with AML, suggesting that FLT3 mutations are involved in disease progression.
  • [MeSH-major] Leukemia, Myeloid / genetics. Mutation. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Acute Disease. Adult. DNA Mutational Analysis / methods. Gene Duplication. Humans. Mutation, Missense. Point Mutation. Sequence Deletion

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16502586.001).
  • [ISSN] 1543-1894
  • [Journal-full-title] Methods in molecular medicine
  • [ISO-abbreviation] Methods Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


36. Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruiter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H: Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol; 2010 Aug 20;28(24):3890-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
  • PURPOSE: Acute myeloid leukemia (AML) with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) [inv(3)/t(3;3)] is recognized as a distinctive entity in the WHO classification.
  • Risk assignment and clinical and genetic characterization of AML with chromosome 3q abnormalities other than inv(3)/t(3;3) remain largely unresolved.
  • PATIENTS AND METHODS: Cytogenetics, molecular genetics, therapy response, and outcome analysis were performed in 6,515 newly diagnosed adult AML patients.
  • Patients were treated on Dutch-Belgian Hemato-Oncology Cooperative Group/Swiss Group for Clinical Cancer Research (HOVON/SAKK; n = 3,501) and German-Austrian Acute Myeloid Leukemia Study Group (AMLSG; n = 3,014) protocols.
  • RESULTS: 3q abnormalities were detected in 4.4% of AML patients (288 of 6,515).
  • Group D 3q aberrant AML also had a poor outcome related to the coexistence of complex and/or monosomal karyotypes and cryptic inv(3)/t(3;3).
  • CONCLUSION: Various categories of 3q abnormalities in AML can be distinguished according to their clinical, hematologic, and genetic features.
  • AML with inv(3)/t(3;3) represents a distinctive subgroup with unfavorable prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Inversion. Chromosomes, Human, Pair 3. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Chromosome Aberrations. Clinical Trials as Topic. DNA-Binding Proteins. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Genes, ras. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Karyotyping. Male. Middle Aged. Monosomy. Multivariate Analysis. Mutation. Neoplasm Proteins / metabolism. Odds Ratio. Predictive Value of Tests. Prognosis. Proto-Oncogenes. Remission Induction. Transcription Factors. Translocation, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20660833.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / DNA-Binding Proteins; 0 / EVL protein, human; 0 / MECOM protein, human; 0 / Neoplasm Proteins; 0 / Transcription Factors
  •  go-up   go-down


37. Haferlach T, Kohlmann A, Schnittger S, Dugas M, Hiddemann W, Kern W, Schoch C: Global approach to the diagnosis of leukemia using gene expression profiling. Blood; 2005 Aug 15;106(4):1189-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Global approach to the diagnosis of leukemia using gene expression profiling.
  • We analyzed gene expression profiles in 937 bone marrow and peripheral blood samples from 892 patients with all clinically relevant leukemia subtypes and from 45 nonleukemic controls by U133A and U133B GeneChip arrays.
  • In particular, acute myeloid leukemia (AML) with t(15;17), AML with t(8;21), AML with inv(16), chronic lymphatic leukemia (CLL), and pro-B-cell acute lymphoblastic leukemia (pro-B-ALL) with t(11q23) were classified with 100% sensitivity and 100% specificity.
  • Gene expression profiling can predict all clinically relevant subentities of leukemia with high accuracy.
  • [MeSH-major] Gene Expression Profiling. Leukemia / diagnosis. Molecular Diagnostic Techniques / standards
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cluster Analysis. Humans. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878973.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Zhao L, Cannons JL, Anderson S, Kirby M, Xu L, Castilla LH, Schwartzberg PL, Bosselut R, Liu PP: CBFB-MYH11 hinders early T-cell development and induces massive cell death in the thymus. Blood; 2007 Apr 15;109(8):3432-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies suggest that the chromosome 16 inversion, associated with acute myeloid leukemia M4Eo, takes place in hematopoietic stem cells.
  • In a conditional knock-in model in which Cbfb-MYH11 expression was activated by Lck-Cre, there was a 10-fold reduction in thymocyte numbers in adult thymus, resulting mainly from impaired survival of CD4+CD8+ thymocytes.
  • Our data suggest that Cbfb-MYH11 suppressed Cbfb in several stages of T-cell development and provide a mechanism for CBFB-MYH11 association with myeloid but not lymphoid leukemia.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 15;156(2):175-8 [15642400.001]
  • [Cites] J Immunol. 1997 Dec 1;159(11):5318-28 [9548471.001]
  • [Cites] Annu Rev Immunol. 2005;23:601-49 [15771582.001]
  • [Cites] Blood. 2005 Jul 15;106(2):494-504 [15784726.001]
  • [Cites] Nat Rev Immunol. 2005 Jul;5(7):571-7 [15999096.001]
  • [Cites] Mol Cell Biol. 2005 Dec;25(23):10205-19 [16287839.001]
  • [Cites] Cancer Cell. 2006 Jan;9(1):57-68 [16413472.001]
  • [Cites] Blood. 2007 Jan 1;109(1):11-21 [16940420.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2449-56 [12239155.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1083-96 [12453416.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):639-44 [12434156.001]
  • [Cites] Cell. 2002 Nov 27;111(5):621-33 [12464175.001]
  • [Cites] Blood Cells Mol Dis. 2003 Mar-Apr;30(2):164-9 [12732179.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7731-6 [12796513.001]
  • [Cites] Blood. 2004 Jan 15;103(2):562-70 [14504086.001]
  • [Cites] Oncogene. 2000 Jan 6;19(1):106-14 [10644985.001]
  • [Cites] EMBO J. 2000 Jun 15;19(12):3004-15 [10856244.001]
  • [Cites] EMBO J. 2001 Feb 15;20(4):723-33 [11179217.001]
  • [Cites] Cell. 2001 Mar 9;104(5):755-67 [11257229.001]
  • [Cites] Int Rev Immunol. 2001 Feb;20(1):45-64 [11342297.001]
  • [Cites] Immunity. 2001 Nov;15(5):763-74 [11728338.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11590-5 [9751710.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):7432-43 [9819429.001]
  • [Cites] Development. 1999 Jun;126(11):2563-75 [10226014.001]
  • [Cites] Nat Struct Biol. 1999 Jul;6(7):620-3 [10404215.001]
  • [Cites] Nat Struct Biol. 1999 Jul;6(7):624-7 [10404216.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):144-6 [10508507.001]
  • [Cites] Immunity. 1999 Sep;11(3):281-8 [10514006.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):451-61 [14706337.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):15678-87 [14747476.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4924-9 [15044690.001]
  • [Cites] Oncogene. 2004 May 24;23(24):4297-307 [15156186.001]
  • [Cites] Adv Immunol. 2004;84:201-38 [15246254.001]
  • [Cites] Cell. 1991 Nov 29;67(5):879-88 [1835668.001]
  • [Cites] Science. 1993 Feb 5;259(5096):822-5 [8430336.001]
  • [Cites] Virology. 1993 May;194(1):314-31 [8386878.001]
  • [Cites] Mol Cell Biol. 1993 Jun;13(6):3324-39 [8497254.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6859-63 [8341710.001]
  • [Cites] Science. 1993 Aug 20;261(5124):1041-4 [8351518.001]
  • [Cites] Cell. 1994 Jun 17;77(6):917-29 [8004678.001]
  • [Cites] EMBO J. 1994 Aug 1;13(15):3570-9 [8062832.001]
  • [Cites] Blood. 1995 Oct 15;86(8):2906-12 [7579382.001]
  • [Cites] Immunity. 1995 Oct;3(4):521-30 [7584142.001]
  • [Cites] Cell. 1996 Jan 26;84(2):321-30 [8565077.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3444-9 [8622955.001]
  • [Cites] Cell. 1996 Nov 15;87(4):687-96 [8929537.001]
  • [Cites] Cell. 1996 Nov 15;87(4):697-708 [8929538.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Cell. 1997 Nov 28;91(5):661-72 [9393859.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3526-33 [15749889.001]
  • (PMID = 17185462.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096983; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Cbfb protein, mouse; 0 / Core Binding Factor beta Subunit; 0 / Oncogene Proteins, Fusion; EC 3.6.4.1 / Myosin Heavy Chains
  • [Other-IDs] NLM/ PMC1852246
  •  go-up   go-down


39. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR: Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol; 2010 Feb 1;28(4):562-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
  • Approximately one third of these patients were classified as having acute myeloid leukemia (AML) under current WHO criteria.
  • CONCLUSION: In older adult patients with low marrow blast count (20% to 30%) WHO-defined AML, azacitidine significantly prolongs OS and significantly improves several patient morbidity measures compared with CCR.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Azacitidine / therapeutic use. Blast Crisis / pathology. Bone Marrow Cells / pathology. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / mortality


40. Grigg AP, Gibson J, Bardy PG, Reynolds J, Shuttleworth P, Koelmeyer RL, Szer J, Roberts AW, To LB, Kennedy G, Bradstock KF: A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Biol Blood Marrow Transplant; 2007 May;13(5):560-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
  • The role of allogeneic transplantation in patients with de novo acute myeloid leukemia in first complete remission (AML-CR1) is controversial.
  • Aiming to preserve a graft-versus-leukemia effect, but minimize morbidity and mortality from conditioning-related toxicity and graft-versus-host disease (GVHD), we conducted a prospective multicenter study of reduced-intensity conditioning (RIC) as preparation for peripheral blood stem cell sibling allografts in patients with intermediate or poor risk AML-CR1.
  • The overall incidence of grade II-IV acute GVHD was low (21%), but the 3 patients (9%) who developed grade IV GVHD died.
  • Donor T cell chimerism was rapid and generally complete, but complete myeloid chimerism was delayed.
  • These observations justify a prospective comparison of RIC versus myeloablative conditioning allografts for AML-CR1.
  • [MeSH-major] Acute Disease / therapy. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy. Peripheral Blood Stem Cell Transplantation / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Chimerism. Cyclophosphamide / therapeutic use. Disease-Free Survival. Female. Fertility. Graft vs Host Disease. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Male. Middle Aged. Prospective Studies. Transplantation, Homologous / methods. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448915.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


41. Abou-Shamaa LA, Mahmoud GN: Leukocytic-vascular endothelial growth factor and integrin alphavbeta3 in acute myeloid leukemia: relation to clinical outcome. Egypt J Immunol; 2008;15(2):81-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukocytic-vascular endothelial growth factor and integrin alphavbeta3 in acute myeloid leukemia: relation to clinical outcome.
  • Different signaling routes seem to be simultaneously triggered in leukemia, with distinct and overlapping activities.
  • The current study was undertaken to investigate leukocytic-VEGF and integrin alphavbeta3 as correlated with clinical outcome in patients with acute myeloid leukemia (AML).
  • The study groups included 10 newly diagnosed AML patients before the start of any chemotherapeutic medication and 10 normal healthy control subjects.
  • Obtained results showed that the level of VEGF and degree of expression of integrin alphavbeta3 were significantly higher in AML patients than in normal healthy subjects.
  • In conclusion, our results proved the importance of VEGF and integrin alphavbeta3 in the pathogenesis of AML.
  • However, the per se increased production or/and secretion of VEGF and integrin alphavbeta3 by leukemic PBMN cells, respectively can not be used as independent predictor (s) for clinical outcome in AML patients.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306691.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


42. Han HS, Rybicki LA, Thiel K, Kalaycio ME, Sobecks R, Advani A, Brown S, Sekeres MA: White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia. Leuk Lymphoma; 2007 Aug;48(8):1561-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia.
  • Kinetics of white blood cell (WBC) elimination following induction chemotherapy for older adults with acute myeloid leukemia (AML) may serve as a surrogate for its effectiveness and safety by enabling real-time prognostication.
  • We reviewed 122 older adults with AML treated at the Cleveland Clinic.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Female. Humans. Leukocyte Count. Male. Middle Aged. Prognosis. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701588.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Fanci R, Bartolozzi B, Longo G, Bosi A: A prospective, open-label noncomparative study with piperacillin-tazobactam monotherapy as management of fever in patients with acute leukemia. J Chemother; 2008 Aug;20(4):492-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective, open-label noncomparative study with piperacillin-tazobactam monotherapy as management of fever in patients with acute leukemia.
  • We evaluated the efficacy of piperacillin-tazobactam monotherapy as empiric therapy of fever in acute leukemia patients in a total of 80 consecutive febrile episodes.
  • Our study suggests that empirical first-line monotherapy with piperacillin-tazobactam may be a reasonable option in patients with acute leukaemia, although in documented infections the response is frequently inadequate.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Fever / drug therapy. Fever / etiology. Leukemia, Myeloid, Acute / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Penicillanic Acid / analogs & derivatives. Penicillanic Acid / therapeutic use. Piperacillin / therapeutic use. Prospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676231.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 157044-21-8 / piperacillin, tazobactam drug combination; 87-53-6 / Penicillanic Acid; X00B0D5O0E / Piperacillin
  •  go-up   go-down


44. Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA, Tallman MS, Bennett JM, Stirewalt DL, Meshinchi S, Willman CL, Ravindranath Y, Alonzo TA, Carroll AJ, Raimondi SC, Heerema NA: A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia; 2006 Jul;20(7):1295-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies.
  • [MeSH-major] Chromosomes, Human, Pair 6. Chromosomes, Human, Pair 9. Leukemia, Myeloid / genetics. Leukemia, Myeloid / therapy. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Child. Child, Preschool. Clinical Trials as Topic. Female. Humans. Male. Middle Aged. Multicenter Studies as Topic. Prognosis. Prospective Studies. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628187.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / CA13539; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA30969; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / K23 CA92405
  • [Publication-type] Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. Chen YX, Ma XR, Zhang WG, Liu J, Cao XM, He AL: [Efficiency of GHA priming chemotherapy on patients with refractory acute myeloid leukemia and myelodysplastic syndrome and its relationship with expression of costimulatory molecule B7.1]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct;16(5):1002-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficiency of GHA priming chemotherapy on patients with refractory acute myeloid leukemia and myelodysplastic syndrome and its relationship with expression of costimulatory molecule B7.1].
  • This study was purposed to explore the clinical efficiency and side effects of GHA (G-CSF, homoharringtonine and low-dose cytarabine) priming chemotherapy for patients with refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and its relationship with B7.1 expression.
  • 79 cases of refractory AML and 21 cases of MDS were treated with GHA standard priming chemotherapy.
  • The results showed that the remission rate in AML was 60.7% (complete remission rate was 43% and partial remission rate was 17.7%), and that was 52.4% in MDS.
  • The higher CR rate was in AML-M(2) and AML-M(5) (60.9%, 61.9%), and the longest remission period was 4 years; expression rate of costimulatory molecule B7.1 displayed large variance (0% - 66.7%) and had positive correlation with efficiency of priming chemotherapy.
  • The rate of B7.1 expression was higher in AML-M(2) and AML-M(5) and lower in other AML groups and normal control.
  • It is concluded that GHA priming chemotherapy can be used to treat refractory AML and MDS, without severe side effects, toxicity and therapy-related mortality.


46. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, Ben Abdelali R, Macintyre E, De Braekeleer E, De Braekeleer M, Delabesse E, de Oliveira MP, Cavé H, Clappier E, van Dongen JJ, Balgobind BV, van den Heuvel-Eibrink MM, Beverloo HB, Panzer-Grümayer R, Teigler-Schlegel A, Harbott J, Kjeldsen E, Schnittger S, Koehl U, Gruhn B, Heidenreich O, Chan LC, Yip SF, Krzywinski M, Eckert C, Möricke A, Schrappe M, Alonso CN, Schäfer BW, Krauter J, Lee DA, Zur Stadt U, Te Kronnie G, Sutton R, Izraeli S, Trakhtenbrot L, Lo Nigro L, Tsaur G, Fechina L, Szczepanski T, Strehl S, Ilencikova D, Molkentin M, Burmeister T, Dingermann T, Klingebiel T, Marschalek R: New insights to the MLL recombinome of acute leukemias. Leukemia; 2009 Aug;23(8):1490-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New insights to the MLL recombinome of acute leukemias.
  • Chromosomal rearrangements of the human MLL gene are associated with high-risk pediatric, adult and therapy-associated acute leukemias.
  • Genomic DNA was isolated from individual acute leukemia patients to identify and characterize chromosomal rearrangements involving the human MLL gene.
  • A total of 760 MLL-rearranged biopsy samples obtained from 384 pediatric and 376 adult leukemia patients were characterized at the molecular level.
  • The distribution of MLL breakpoints for clinical subtypes (acute lymphoblastic leukemia, acute myeloid leukemia, pediatric and adult) and fused translocation partner genes (TPGs) will be presented, including novel MLL fusion genes.
  • [MeSH-major] Leukemia / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. Recombination, Genetic. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Adult. Biopsy. Bone Marrow / chemistry. Bone Marrow / pathology. Child. Chromosome Breakage. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 11 / ultrastructure. Computational Biology. DNA, Neoplasm / blood. DNA, Neoplasm / genetics. Gene Duplication. Histone-Lysine N-Methyltransferase. Humans. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19262598.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / MLL protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


47. Kato T, Kawana S, Takezaki S, Kikuchi S, Futagami A: Case of Sweet's syndrome with extensive necrosis and ulcers accompanied by myelodysplastic syndrome. J Nippon Med Sch; 2008 Jun;75(3):162-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six months later, myelodysplastic syndrome had progressed to acute myelogenous leukemia.
  • [MeSH-minor] Adult. Conjunctiva / pathology. Diagnosis, Differential. Disease Progression. Female. Humans. Leukemia, Myeloid, Acute / etiology. Prednisolone / adverse effects. Prednisolone / therapeutic use. Skin / pathology

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648174.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


48. Ahmad F, Mandava S, Das BR: Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, correlation with cytogenetics and characterization of internal tandem duplication from Indian population. Cancer Invest; 2010 Jan;28(1):63-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, correlation with cytogenetics and characterization of internal tandem duplication from Indian population.
  • Here, we found FLT3-ITD mutations in 19.1%, FLT3-Asp835 mutations in 4.7%, and dual mutations in 4.2%, accounting for overall mutation in 28% of acute myeloid leukemia (AML) patients.
  • FLT3 mutation was more prevalent in APL than non-APL patients (32.2% vs 26.3%), adults tend to show higher incidence than children (30.6% vs 18.2%, p = .1), and were significantly associated with normal karyotype, high WBCs, with no specific distribution in FAB subtypes.
  • [MeSH-major] Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / genetics. Point Mutation. Tandem Repeat Sequences. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amino Acid Sequence. Child. Child, Preschool. DNA Mutational Analysis. Female. Gene Frequency. Humans. In Situ Hybridization, Fluorescence. India / epidemiology. Infant. Karyotyping. Male. Middle Aged. Molecular Sequence Data. Nuclear Proteins / genetics. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19995225.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


49. Zhou FL, Zhang WG, Wei YC, Meng S, Bai GG, Wang BY, Yang HY, Tian W, Meng X, Zhang H, Chen SP: Involvement of oxidative stress in the relapse of acute myeloid leukemia. J Biol Chem; 2010 May 14;285(20):15010-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of oxidative stress in the relapse of acute myeloid leukemia.
  • The aims of the present study were to determine the level of oxidative stress and the salient factors leading to the relapse of acute myeloid leukemia (AML).
  • Oxidative stress-related parameters and the expressions of specific genes were monitored in 102 cases of AML during a pretreatment period from a primary status to a relapse status.
  • These results indicate that oxidative stress is a crucial feature of AML and probably affects the development and relapse of AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / metabolism. Oxidative Stress
  • [MeSH-minor] Adenosine Deaminase / metabolism. Adolescent. Adult. Aged. Base Sequence. Case-Control Studies. DNA Primers. Female. Glutathione Peroxidase / metabolism. Humans. Male. Middle Aged. Monoamine Oxidase / metabolism. Recurrence. Superoxide Dismutase / metabolism. Xanthine Oxidase / metabolism. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Care Med. 2009 Jul;37(7):2155-9 [19487947.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1379-86 [16923572.001]
  • [Cites] Leuk Res. 2007 Mar;31(3):387-93 [16949154.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):792-801 [17234791.001]
  • [Cites] J Pharm Pharmacol. 2007 Mar;59(3):409-17 [17331345.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12288-93 [17640917.001]
  • [Cites] Immunol Lett. 2007 Aug 15;111(2):69-75 [17644189.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2616-20 [17564752.001]
  • [Cites] Diabetes. 2008 Apr;57(4):879-88 [18003754.001]
  • [Cites] Clin Biochem. 2008 May;41(7-8):511-8 [18313403.001]
  • [Cites] Leuk Res. 2008 Aug;32(8):1221-7 [18313749.001]
  • [Cites] Acta Physiol Hung. 2008 Jun;95(2):209-18 [18642760.001]
  • [Cites] Gen Physiol Biophys. 2008 Jun;27(2):71-84 [18645221.001]
  • [Cites] Antioxid Redox Signal. 2008 Oct;10(10):1813-48 [18593226.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1685-91 [18580952.001]
  • [Cites] Pediatr Blood Cancer. 2008 Nov;51(5):613-5 [18623225.001]
  • [Cites] Biomed Environ Sci. 2008 Aug;21(4):286-9 [18837290.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Oct;295(4):C849-68 [18684987.001]
  • [Cites] Leukemia. 2008 Oct;22(10):1969-72 [18401418.001]
  • [Cites] Pediatr Blood Cancer. 2008 Dec;51(6):741-6 [18680148.001]
  • [Cites] Free Radic Biol Med. 2008 Sep 15;45(6):875-84 [18638547.001]
  • [Cites] Haematologica. 2008 Dec;93(12):1894-8 [19050070.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Feb;135(2):319-23 [18758816.001]
  • [Cites] Mol Nutr Food Res. 2009 Jan;53(1):87-103 [18979503.001]
  • [Cites] Leuk Res. 2009 Mar;33(3):490-4 [18639339.001]
  • [Cites] Zhongguo Dang Dai Er Ke Za Zhi. 2009 Feb;11(2):88-92 [19222940.001]
  • [Cites] Circ Res. 2009 Mar 27;104(6):750-7 [19179658.001]
  • [Cites] Oncologist. 2009 Mar;14(3):240-52 [19289488.001]
  • [Cites] J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009 Apr;27(2):120-39 [19412858.001]
  • [Cites] Cell Death Differ. 2009 Jun;16(6):847-57 [19247368.001]
  • [Cites] Leuk Res. 2009 Oct;33(10):1367-71 [19327827.001]
  • [Cites] Leuk Res. 2009 Oct;33(10):1297 [19560202.001]
  • [Cites] Nephron Clin Pract. 2009;112(4):c255-61 [19546585.001]
  • [Cites] Int J Neuropsychopharmacol. 2009 Sep;12(8):1089-96 [19272208.001]
  • [Cites] Environ Toxicol. 2009 Oct;24(5):446-52 [18979530.001]
  • [Cites] Cancer Biol Ther. 2009 Jul;8(14):1402-8 [19597340.001]
  • [Cites] Yonsei Med J. 2009 Oct 31;50(5):677-82 [19881972.001]
  • [Cites] J Mol Endocrinol. 2009 Dec;43(6):251-61 [19620238.001]
  • [Cites] Leuk Res. 2000 Jun;24(6):461-8 [10781678.001]
  • [Cites] Free Radic Biol Med. 2001 Jun 1;30(11):1286-92 [11368926.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 18;319(1):41-5 [15158439.001]
  • [Cites] J Clin Lab Anal. 1992;6(1):47-53 [1542083.001]
  • [Cites] Mol Cell Biochem. 2004 Nov;266(1-2):37-56 [15646026.001]
  • [Cites] Clin Chem Lab Med. 2005;43(3):294-7 [15843234.001]
  • [Cites] Drug Resist Updat. 2005 Oct;8(5):322-30 [16230045.001]
  • [Cites] Chem Biol Interact. 2006 Mar 10;160(1):1-40 [16430879.001]
  • [Cites] Perit Dial Int. 2006 Mar-Apr;26(2):207-12 [16623427.001]
  • [Cites] Toxicology. 2007 Jan 5;229(1-2):1-10 [17118505.001]
  • (PMID = 20233720.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase; EC 1.17.3.2 / Xanthine Oxidase; EC 1.4.3.4 / Monoamine Oxidase; EC 3.5.4.4 / Adenosine Deaminase
  • [Other-IDs] NLM/ PMC2865279
  •  go-up   go-down


50. Yilmaz M, Dagdas S, Aki SZ, Guler N, Akoz AG, Erdin Z, Alanoglu G, Ozet G: The relation between plasminogen activator inhibitor activity and disease activation in acute myeloblastic leukaemia patients. Clin Lab Haematol; 2006 Oct;28(5):313-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relation between plasminogen activator inhibitor activity and disease activation in acute myeloblastic leukaemia patients.
  • Coagulation and fibrinolytic abnormalities are common in patients with acute myeloblastic leukaemia (AML) like other forms of leukaemias.
  • In this study, we investigated if total plasminogen activator inhibitor (PAI) activity, which is believed to increase in initial diagnosis and relapse in AML patients could be accepted as a relapse criterion or not.
  • Total of 34 AML patients and 18 healthy volunteers were included in this study.
  • Total PAI activity was higher than 3.5 U/ml in 11 AML patients while it was normal (0.3-3.5 U/ml) in control group (P < 0.01).
  • There was no significant difference in total PAI activity between AML subgroups (P > 0.05).
  • In conclusion, the total PAI activity could be accepted as a relapse and an initial diagnosis criterion of AML patients during follow up.
  • [MeSH-major] Leukemia, Myeloid, Acute / blood. Plasminogen Activator Inhibitor 1 / blood. Plasminogen Activator Inhibitor 2 / blood
  • [MeSH-minor] Adult. Biomarkers / blood. Chi-Square Distribution. Female. Humans. Male. Recurrence

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16999721.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Plasminogen Activator Inhibitor 1; 0 / Plasminogen Activator Inhibitor 2
  •  go-up   go-down


51. Pavletic S, Vogelsand GB: Treatment of high-risk chronic GVHD. Biol Blood Marrow Transplant; 2008 Dec;14(12):1436-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Acute Disease. Adult. Chronic Disease. Drug Eruptions. Female. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / adverse effects. Leukemia, Myeloid, Acute / therapy. Male. Peripheral Blood Stem Cell Transplantation. Risk. Steroids / administration & dosage. Steroids / adverse effects. Tacrolimus / administration & dosage. Tacrolimus / adverse effects. Transplantation Conditioning. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041069.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Steroids; WM0HAQ4WNM / Tacrolimus
  • [Number-of-references] 9
  •  go-up   go-down


52. Chen CC, Gau JP, Yu YB, Lu CH, Lee KD, You JY: Prognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22). Adv Ther; 2007 Jul-Aug;24(4):907-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis and treatment outcome in patients with acute myeloid leukemia with t(8;21)(q22;q22).
  • Patients with acute myeloid leukemia (AML) with the t(8;21) karyotype generally have a favorable clinical course, but key prognostic factors remain poorly defined.
  • This study was conducted to determine the prognoses and treatment outcomes of patients with AML with this unique cytogenetic change.
  • A total of 22 patients with AML with t(8;21)(q22;q22) were studied.
  • Another 55 patients with AML with a normal karyotype were included for comparison of clinical outcomes.
  • The data presented here suggest that t(8;21)(q22;q22) cytogenetic changes in patients with AML had prognostic significance similar to that in patients with a normal karyotype; patients who harbored either karyotype had parallel clinical outcomes.
  • It is concluded that patients with AML with t(8;21)(q22;q22) would be compromised by treatment approaches that do not include HSCT as postremission therapy.
  • [MeSH-major] Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Hematologic Tests. Hematopoietic Stem Cell Transplantation. Humans. Karyotyping. Male. Middle Aged. Prognosis. Translocation, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17901040.001).
  • [ISSN] 0741-238X
  • [Journal-full-title] Advances in therapy
  • [ISO-abbreviation] Adv Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Locke FL, Artz A, Rich E, Zhang Y, van Besien K, Stock W: Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant; 2010 Dec;45(12):1692-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.
  • To control disease before allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory AML, we used clofarabine cytoreduction.
  • Outcomes for this cohort of patients with refractory AML remain poor and we are studying this approach in a prospective manner.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / drug therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20208570.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K24 CA116471
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  •  go-up   go-down


54. Hutchinson CV, Burthem J, Bisland M, Carey P, Crotty G, Devalia V, Janda B, Gordon W, Harrison CN, Murray J, Shlebak A, Thomas A, Wilkins B, McMullin MF: British Society for Haematology, slide session, annual scientific meeting, Glasgow, 2008. Int J Lab Hematol; 2010 Apr;32(2):174-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Anemia, Refractory, with Excess of Blasts / pathology. Child, Preschool. Clinical Laboratory Techniques. Cytogenetic Analysis. Female. Hematologic Tests. History, 21st Century. Humans. Leukemia, Myeloid, Acute / pathology. Leukemia, Promyelocytic, Acute / pathology. Male. Scotland

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19364371.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Congresses; Historical Article
  • [Publication-country] England
  •  go-up   go-down


55. Zhang JY, Lü T, Yang JC, Pan L, Luo JM, Yang L, Yao L, Dong ZR, Xu SR: Comparative study of expressions of cytoplasmic CD79a and other B-lymphoid immunomarkers in acute leukemic cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec;13(6):954-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative study of expressions of cytoplasmic CD79a and other B-lymphoid immunomarkers in acute leukemic cells.
  • To evaluate the expression of cytoplasmic CD79a (CyCD79a) and other commonly used B-lymphoid immunomarkers including cytoplasmic CD22 (CyCD22), CD19, CD20 and CD10 in various acute leukemia cells and to define the most sensitive and specific markers in the diagnosis of precursor B-cell acute lymphoblastic leukemia (pB-ALL), the immunophenotypic data from 221 de novo adult and pediatric acute leukemia patients as studied using multi-parameter flow cytometry in addition to routine morphologic and enzyme cytochemical assay, were retrospectively analyzed.
  • Cytogenetic and/or molecular biological data in all 45 cases of acute promyelocytic leukemia (APL) and 13 cases of acute leukemia suspected as AML with the fusion genes such as AML1/ETO and CBFbeta/MYH11 were investigated.
  • At the same time, none (0%) of all 147 cases of acute myeloid leukemia (AML) and 15 cases of precursor T-cell acute leukemia (pT-ALL) was positive for CyCD22.
  • The conclusion is made that united detection of CyCD79a and CyCD22 is the optimal immune combination for the diagnosis pB-ALL and the distinguishing pB-ALL with AML and pT-ALL.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403258.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD79; 0 / Biomarkers, Tumor; 0 / Sialic Acid Binding Ig-like Lectin 2
  •  go-up   go-down


56. Raaijmakers MH, de Grouw EP, van der Reijden BA, de Witte TJ, Jansen JH, Raymakers RA: ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia. Clin Cancer Res; 2006 Jun 1;12(11 Pt 1):3452-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia.
  • PURPOSE: Acute myelogenous leukemia (AML) is a disease originating from normal hematopoietic CD34+ CD38- progenitor cells.
  • Modulation of the multidrug ATP-binding cassette transporter ABCB1 has not resulted in improved outcome in AML, raising the question whether leukemic CD34+ CD38- cells are targeted by this strategy.
  • Surprisingly, ABCB1-mediated drug extrusion was invariably reduced in CD34+ CD38- cells in AML (n = 15; EI, 1.21 +/- 0.05; P < 0.001), which resulted in increased intracellular mitoxantrone retention in these cells (mitoxantrone fluorescence intensity, 4.54 +/- 0.46 versus 3.08 +/- 0.23; P = 0.004).
  • These data argue that ABCB1 modulation is not an effective strategy to circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal progenitors in AML.
  • [MeSH-major] Hematopoietic Stem Cells / drug effects. Leukemia, Myeloid, Acute / drug therapy. P-Glycoprotein / drug effects
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD34 / biosynthesis. Antigens, CD38 / analysis. Antigens, Differentiation / biosynthesis. Biological Transport / drug effects. Bone Marrow Cells / drug effects. Bone Marrow Cells / immunology. Cyclosporins / pharmacology. Drug Resistance, Multiple. Female. Flow Cytometry. Humans. Male. Middle Aged. Mitoxantrone / antagonists & inhibitors. Mitoxantrone / metabolism. Mitoxantrone / pharmacology. Oncogene Proteins, Fusion / biosynthesis. Oncogene Proteins, Fusion / genetics. P-Glycoproteins. Reverse Transcriptase Polymerase Chain Reaction / methods. Verapamil / pharmacology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3231-2 [16740740.001]
  • (PMID = 16740770.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antigens, CD34; 0 / Antigens, Differentiation; 0 / CBFbeta-MYH11 fusion protein; 0 / Cyclosporins; 0 / Oncogene Proteins, Fusion; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 121584-18-7 / valspodar; BZ114NVM5P / Mitoxantrone; CJ0O37KU29 / Verapamil; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


57. Chevallier P, Robillard N, Ayari S, Guillaume T, Delaunay J, Mechinaud F, Avet-Loiseau H, Mohty M, Harousseau JL, Garand R: Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease. Br J Haematol; 2008 Dec;143(5):744-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antigens, CD / blood. Antigens, Differentiation, Myelomonocytic / blood. Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Humanized. Child, Preschool. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Sialic Acid Binding Ig-like Lectin 3. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036018.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab
  •  go-up   go-down


58. Kopp M, Holzner B, Meraner V, Sperner-Unterweger B, Kemmler G, Nguyen-Van-Tam DP, Nachbaur D: Quality of life in adult hematopoietic cell transplant patients at least 5 yr after treatment: a comparison with healthy controls. Eur J Haematol; 2005 Apr;74(4):304-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life in adult hematopoietic cell transplant patients at least 5 yr after treatment: a comparison with healthy controls.
  • This is consistent with Kiss et al. (J Clin Oncol 2002;20:2334-2343), who found that chronic myeloid leukemia patients who were alive at least 10 yr after HCT report lower physical functioning in comparison to healthy controls.
  • Interdisciplinary (medical, psychological and social) treatment of patients should not come to an end after the acute phase of the illness but should continue during check-ups following transplantation.
  • [MeSH-minor] Adult. Austria. Case-Control Studies. Female. Hematologic Neoplasms / physiopathology. Hematologic Neoplasms / psychology. Hematologic Neoplasms / therapy. Humans. Male. Middle Aged. Quality of Life. Surveys and Questionnaires. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Blackwell Munksgaard.
  • (PMID = 15777342.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


59. Oestreicher P: Recognize hepatic sinusoidal obstruction syndrome in patients with cancer. ONS Connect; 2008 Mar;23(3):22-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Humans. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / therapy. Male. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432087.001).
  • [ISSN] 1935-1623
  • [Journal-full-title] ONS connect
  • [ISO-abbreviation] ONS Connect
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 1
  •  go-up   go-down


60. Amitrano L, Guardascione MA, Schiavone EM, Brancaccio V, Antinolfi I, Iannaccone L, Ferrara F, Balzano A: Hepatic vein thrombosis leading to fulminant hepatic failure in a case of acute non-promyelocytic myelogenous leukemia. Blood Coagul Fibrinolysis; 2006 Jan;17(1):59-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic vein thrombosis leading to fulminant hepatic failure in a case of acute non-promyelocytic myelogenous leukemia.
  • Budd-Chiari syndrome is a rare disease due to occlusion of the hepatic veins often presenting with acute liver failure.
  • Common causes of Budd-Chiari syndrome are chronic myeloproliferative disorders, while acute leukemia has been associated with hepatic vein thrombosis in only two cases in the literature to date.
  • We report a case of Budd-Chiari syndrome complicating a non-promyelocytic acute myelogenous leukemia leading to fulminant hepatic failure.
  • [MeSH-major] Budd-Chiari Syndrome / etiology. Leukemia, Myeloid, Acute / complications. Liver Failure, Acute / etiology
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Tomography, X-Ray Computed


61. Chang H, Nayar R, Li D, Sutherland DR: Clonality analysis of cell lineages in acute myeloid leukemia with inversion 16. Cancer Genet Cytogenet; 2005 Jan 15;156(2):175-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonality analysis of cell lineages in acute myeloid leukemia with inversion 16.
  • Bone marrow from 5 patients with acute myeloid leukemia with inversion 16, inv(16), was studied by a combination of fluorescence activated cell sorting (FACS) and fluorescence in situ hybridization (FISH) to establish the extent of cell-lineage involvement of inv(16).
  • The current study provides a direct evidence for the clonal involvement of myeloid lineage cells and B-lymphocytes and suggests that T-cells are not part of the malignant clone in this disease.
  • [MeSH-major] Chromosome Inversion / genetics. Chromosomes, Human, Pair 16. Leukemia, Myeloid / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Bone Marrow Cells / pathology. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642400.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Steensma DP: A cello for Michayla. J Clin Oncol; 2010 Oct 1;28(28):4400-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Leukemia, Myeloid, Acute / psychology. Mother-Child Relations. Music
  • [MeSH-minor] Adult. Child. Female. Humans

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20660826.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Manola KN, Sambani C, Karakasis D, Baltathakis I, Zoumbos N, Symeonidis A: Allogeneic stem cell transplantation from donors with mosaic Turner syndrome. Bone Marrow Transplant; 2006 Sep;38(5):385-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Acute Disease. Adult. Child, Preschool. Cytomegalovirus Infections / etiology. Fatal Outcome. Female. Graft vs Host Disease / etiology. Humans. Leukemia, Myeloid / therapy. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Autologous


64. Sada E, Henzan H, Ohtani R, Takase K, Miyamoto T, Fukuda T, Nagafuji K, Yamauchi K, Takamatsu Y, Inaba S, Harada M: Conditioning with targeted busulfan for autologous peripheral blood stem cells transplantation for acute myelogenous leukemia in an XYY male. Am J Hematol; 2005 Jan;78(1):55-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditioning with targeted busulfan for autologous peripheral blood stem cells transplantation for acute myelogenous leukemia in an XYY male.
  • We report herein a 19-year-old Japanese male with XYY syndrome who developed acute myelogenous leukemia.
  • He had no severe regimen-related toxicities and is now free of leukemia.
  • [MeSH-major] Busulfan / administration & dosage. Immunosuppressive Agents / administration & dosage. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / surgery. Peripheral Blood Stem Cell Transplantation. Transplantation Conditioning. XYY Karyotype
  • [MeSH-minor] Adult. Drug Delivery Systems. Humans. Male. Transplantation, Autologous


65. Tian S, Meng FY, Tang JM: [Proteomics analysis of bone marrow cells of acute myeloid leukemia M2a and prognostic significance thereof]. Zhonghua Yi Xue Za Zhi; 2007 Feb 27;87(8):538-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Proteomics analysis of bone marrow cells of acute myeloid leukemia M2a and prognostic significance thereof].
  • OBJECTIVE: To investigate the relationship between the distinct expression of proteins in the leukemic cells of leukemia AML-M(2)a patients before inducible treatment and that of the patients with relapse and the prognosis by proteomics.
  • METHODS: The bone marrow mononuclear cells (BMMNC) from 17 patients with leukemia AML-M(2)a before inductive treatment were divided into 3 groups according to the duration of CCR(1): Group A (n = 11) with the CCR(1) duration exceeding 12 months, Group B (n = 6) with the CCR(1) duration less than 6 months, and Group C, including the 3 cases of Group B with relapse.
  • CONCLUSION: The expression level of distinct proteins of leukemic cells of leukemia AML-M(2)a patients before inductive treatments is associated with the prognosis.
  • [MeSH-major] Bone Marrow Cells / metabolism. Leukemia, Myeloid, Acute / metabolism. Proteomics / methods
  • [MeSH-minor] Adolescent. Adult. Electrophoresis, Gel, Two-Dimensional. Female. Follow-Up Studies. Humans. Male. Middle Aged. Peptide Mapping. Prognosis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459203.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


66. Schmidt-Hieber M, Blau IW, Richter G, Türkmen S, Bommer C, Thiel G, Neitzel H, Stroux A, Uharek L, Thiel E, Blau O: Cytogenetic studies in acute leukemia patients relapsing after allogeneic stem cell transplantation. Cancer Genet Cytogenet; 2010 Apr 15;198(2):135-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic studies in acute leukemia patients relapsing after allogeneic stem cell transplantation.
  • We analyzed karyotype stability in 22 patients with acute leukemia at relapse or disease progression after allogeneic stem cell transplantation (allo-SCT).
  • We identified a previously undescribed clonal evolution involving t(15;17) without PML-RARA rearrangement in an AML patient.
  • We conclude that a karyotype change is common at relapse after allo-SCT in acute leukemia patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Chromosomes, Human. Clone Cells / pathology. Cytogenetic Analysis / methods. Disease Progression. Female. Humans. Immunophenotyping. Male. Middle Aged. Recurrence. Transplantation, Homologous. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [ErratumIn] Cancer Genet Cytogenet. 2010 Jul 1;200(1):73
  • (PMID = 20362228.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Huisman C, de Weger RA, de Vries L, Tilanus MG, Verdonck LF: Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant; 2007 Mar;39(5):285-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia.
  • We monitored chimerism status by short tandem repeat-based polymerase chain reaction (PCR) in T- and non-T-cell subsets and retrospectively evaluated clinical outcome in 96 patients with acute myeloid leukemia after myeloablative (MA) or reduced-intensity conditioning SCT.
  • [MeSH-major] Bone Marrow Transplantation. Chimerism. Leukemia, Myeloid, Acute / genetics. Microsatellite Repeats / genetics. Polymerase Chain Reaction. Transplantation Chimera / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Monitoring, Physiologic / methods. Predictive Value of Tests. Recurrence. Transplantation, Homologous


68. Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, Maisonneuve H, Delwail V, Gressin R, Quittet P, Vilque JP, Desablens B, Jaubert J, Ramée JF, Arakelyan N, Thyss A, Moluçon-Chabrot C, Delépine R, Milpied N, Colombat P, Deconinck E, Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS): High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood; 2009 Jan 29;113(5):995-1001
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secondary malignancies were more frequent in the HDT than in the chemotherapy group (6 secondary myelodysplastic syndrome/acute myeloid leukemia and 6 second solid tumor cancers vs 1 acute myeloid leukemia, P = .01).
  • [MeSH-minor] Adolescent. Adult. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunotherapy / methods. Male. Middle Aged. Myeloablative Agonists / administration & dosage. Survival Rate. Transplantation, Autologous. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955565.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00696735
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


69. Chang CY, Singal AK, Ganeshan SV, Schiano TD, Lookstein R, Emre S: Use of splenic artery embolization to relieve tense ascites following liver transplantation in a patient with paroxysmal nocturnal hemoglobinuria. Liver Transpl; 2007 Nov;13(11):1532-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Anemia, Aplastic / pathology. Female. Humans. Leukemia, Myeloid, Acute / etiology. Liver / pathology. Magnetic Resonance Imaging. Portal Vein / pathology. Thrombosis / etiology. Tomography, X-Ray Computed


70. Kuwatsuka Y, Miyamura K, Suzuki R, Kasai M, Maruta A, Ogawa H, Tanosaki R, Takahashi S, Koda K, Yago K, Atsuta Y, Yoshida T, Sakamaki H, Kodera Y: Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. Blood; 2009 Feb 26;113(9):2096-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes.
  • We analyzed 338 adult patients with acute myeloid leukemia (AML) with t(8;21) and inv(16) undergoing stem cell transplantation (SCT) who were registered in the Japan Society for Hematopoietic Cell Transplantation database.
  • OS was not different between patients in first CR who received allogeneic SCT and those who received autologous SCT for both t(8;21) AML (84% vs 77%; P= .49) and inv(16) AML (74% vs 59%; P= .86).
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 16. Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Core Binding Factors / genetics. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome. Young Adult


71. Burmeister T, Meyer C, Schwartz S, Hofmann J, Molkentin M, Kowarz E, Schneider B, Raff T, Reinhardt R, Gökbuget N, Hoelzer D, Thiel E, Marschalek R: The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group. Blood; 2009 Apr 23;113(17):4011-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group.
  • MLL translocations in adult B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) are largely restricted to the immature CD10(-) immunophenotypes.
  • MLL-AF4 is known to be the most frequent fusion transcript, but the exact frequencies of MLL aberrations in CD10(-) adult BCP-ALL are unknown.
  • We present a genetic characterization of 184 BCR-ABL(-) CD10(-) adult ALL cases (156 cyIg(-), 28 cyIg(+)) diagnosed between 2001 and 2007 at the central diagnostic laboratory of the GMALL study group.
  • [MeSH-major] Myeloid-Lymphoid Leukemia Protein / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Recombinant Fusion Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chromosomes, Human / genetics. Female. Histone-Lysine N-Methyltransferase. Humans. Male. Middle Aged. Neprilysin / metabolism. Societies, Medical

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144982.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00198991/ NCT00199056
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / Recombinant Fusion Proteins; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


72. Sun JF, Han XP, Zhao DD, Wang FF, Jin HJ, Gao CJ, DA WM, Yu L: [Application of chimerism analysis to allogeneic hematopoietic stem cell transplantation by STR-PCR]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr;15(2):337-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 14 patients with 100% donor chimerism (DC) had stable engraftment and they still survive in free leukemia.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493343.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


73. Meshinchi S, Stirewalt DL, Alonzo TA, Boggon TJ, Gerbing RB, Rocnik JL, Lange BJ, Gilliland DG, Radich JP: Structural and numerical variation of FLT3/ITD in pediatric AML. Blood; 2008 May 15;111(10):4930-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural and numerical variation of FLT3/ITD in pediatric AML.
  • FLT3 internal tandem duplication (FLT3/ITD) is a common somatic mutation in acute myeloid leukemia (AML) with significant variation in the position, length, and number of duplications of the FLT3 gene.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2000 Jan 1;28(1):235-42 [10592235.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2776-84 [17957027.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3589-95 [11369655.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1752-9 [11535508.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1474-9 [12702504.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2387-94 [12816873.001]
  • [Cites] Mol Cell. 2004 Jan 30;13(2):169-78 [14759363.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):624-33 [14726504.001]
  • [Cites] Acta Crystallogr A. 1991 Mar 1;47 ( Pt 2):110-9 [2025413.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] JAMA. 2005 Jan 12;293(2):203-11 [15644547.001]
  • [Cites] Blood. 2006 May 1;107(9):3724-6 [16368883.001]
  • [Cites] Blood. 2006 May 1;107(9):3700-7 [16410449.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1339-45 [16627759.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3654-61 [16912228.001]
  • [Cites] Blood. 2007 Jul 15;110(2):686-94 [17387224.001]
  • [Cites] Blood. 2001 Jan 1;97(1):89-94 [11133746.001]
  • (PMID = 18305215.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA18029; United States / NCI NIH HHS / CA / K23 CA92405; United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / K23 CA092405; United States / NCI NIH HHS / CA / CA114563; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / R01 CA114563; United States / NCI NIH HHS / CA / R21 CA102624
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / STAT5 Transcription Factor; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC2384125
  •  go-up   go-down


74. Fung YL, Williams BA: TRALI in 2 cases of leukemia. J Pediatr Hematol Oncol; 2006 Jun;28(6):391-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRALI in 2 cases of leukemia.
  • We describe transfusion-related acute lung injury (TRALI) in 2 acute leukemia cases to increase awareness of this under reported serious transfusion complication syndrome in multitransfused patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Leukemia, Promyelocytic, Acute / complications. Platelet Transfusion / adverse effects. Respiratory Distress Syndrome, Adult / etiology. Respiratory Distress Syndrome, Adult / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. FUROSEMIDE .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2006 Jun;28(6):328-30 [16794498.001]
  • (PMID = 16794510.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Diuretics; 7LXU5N7ZO5 / Furosemide; 9PHQ9Y1OLM / Prednisolone; S88TT14065 / Oxygen
  •  go-up   go-down


75. Jayawardena S, Sooriabalan D, Indulkar S, Kim HH, Matin A, Maini A: Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate. Am J Ther; 2006 Sep-Oct;13(5):458-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of 31-year-old man with grade III astrocytoma with subsequent chronic myelogenous leukemia treated with imatinib mesylate as part of his chronic myelogenous leukemia treatment failing to show recurrence of the astrocytoma 10 years after standard treatment for astrocytoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Benzamides. Combined Modality Therapy. Humans. Imatinib Mesylate. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988542.001).
  • [ISSN] 1075-2765
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


76. Chafai R, Gharbi O, Trabelsi A, Chabchoub I, Lettaif O, Ben Ahmed S: [Granulocytic sarcoma in the mandibular gingiva of an HIV+ patient]. Rev Stomatol Chir Maxillofac; 2010 Jun;111(3):172-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granulocytic sarcoma in the mandibular gingiva of an HIV+ patient].
  • We report a rare case of gingival granulocytic sarcoma (GS) associated to HIV infection.
  • Chemotherapy similar to that of acute myeloid leukemia (AML) completed the treatment.
  • The treatment is comparable to that of AML.
  • [MeSH-major] Gingival Neoplasms / diagnosis. HIV Seropositivity / complications. Mandibular Neoplasms / diagnosis. Sarcoma, Myeloid / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. CD4 Lymphocyte Count. Follow-Up Studies. HIV / isolation & purification. Humans. Male. Maxillary Neoplasms / diagnosis. Maxillary Neoplasms / drug therapy. Remission Induction. Viral Load


77. Raghavan M, Lillington DM, Skoulakis S, Debernardi S, Chaplin T, Foot NJ, Lister TA, Young BD: Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res; 2005 Jan 15;65(2):375-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias.
  • Genome-wide analysis of single nucleotide polymorphisms in 64 acute myeloid leukemias has revealed that approximately 20% exhibited large regions of homozygosity that could not be accounted for by visible chromosomal abnormalities in the karyotype.
  • These cryptic chromosomal abnormalities, which seem to be nonrandom, have the characteristics of somatic recombination events and may define an important new subclass of leukemia.
  • [MeSH-major] Leukemia, Myeloid / genetics. Polymorphism, Single Nucleotide. Uniparental Disomy
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Base Sequence. DNA Methylation. DNA, Neoplasm / genetics. Diploidy. Female. Genome, Human. Humans. Karyotyping. Male. Middle Aged


78. Najima Y, Ohashi K, Kawamura M, Onozuka Y, Yamaguchi T, Akiyama H, Sakamaki H: Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia. Int J Hematol; 2010 May;91(4):636-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia.
  • Recent studies have shown that high BAALC expression predicts an adverse prognosis and may define an important risk factor in acute myeloid leukemia patients with normal karyotype.
  • We performed, using real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR), the molecular analysis of BAALC gene as a possible minimal residual disease (MRD) marker in 45 patients with newly diagnosed acute leukemia.
  • Quantitation of BAALC gene expression made it possible to assess MRD in patients with CD34-positive acute leukemia.
  • [MeSH-major] Biomarkers, Tumor / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / mortality. Neoplasm Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD34 / metabolism. Disease-Free Survival. Female. Gene Expression Regulation, Leukemic. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm, Residual / genetics. Neoplasm, Residual / mortality. Predictive Value of Tests. Prognosis. RNA, Messenger / genetics. Risk Factors. Translocation, Genetic. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Mar 1;101(5):1698-704 [12406915.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1613-8 [12750167.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1416-24 [15746041.001]
  • [Cites] Exp Hematol. 2003 Nov;31(11):1051-6 [14585369.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1803-8 [15223639.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1103-8 [16541144.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13901-6 [11707601.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4714-20 [16954520.001]
  • [Cites] Curr Opin Hematol. 2007 Mar;14(2):106-14 [17255787.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S77-8 [15124683.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2115-21 [12357365.001]
  • [Cites] Semin Hematol. 2003 Apr;40(2 Suppl 2):37-41 [12783374.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):790-7 [16418499.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5371-9 [18378853.001]
  • (PMID = 20376583.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / BAALC protein, human; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


79. Zhao J, Yin YM, Zhao YL, Sun Y, Wang JB, Zhong J, Zhang X, Fei XH, Shan FX, Liu HX, Wang T, Wang H, Tong CR, Wu T, Lu DP: [Clinical and molecular biologic characteristics of 36 cases of leukemia with 11q23/mll]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec;18(6):1381-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and molecular biologic characteristics of 36 cases of leukemia with 11q23/mll].
  • This study was aimed to analyze the clinical and cytogenetic characteristics of acute leukemia with 11q23/mll rearrangement and explore the reasonable therapeutic principles.
  • Characteristics in general situation, morphology, immunology, molecular biology, cytogenetics, treatment and overall survival of 36 cases of acute leukemias with mll gene rearrangement were studied and analyzed.
  • The results showed that 36 cases with mll gene rearrangement were found positive (7.2%) in 494 patients with acute leukemia.
  • Among the 36 cases of mll rearrangement positive, 32 cases were diagnosed as acute myeloid leukemia (AML) with myeloid antigen expression, of which 5 cases expressed lymphoblastic differentiation antigen; 4 cases were classified as B-lineage acute lymphoblastic leukemia (ALL), of which non-lineage myeloid expression pattern were found in 3 cases.
  • It is concluded that acute leukemia patients with mll gene rearrangement show poor response to chemotherapy, high recurrence rate and poor prognosis.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176334.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


80. Ohyashiki JH, Hisatomi H, Nagao K, Honda S, Takaku T, Zhang Y, Sashida G, Ohyashiki K: Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells. Br J Cancer; 2005 May 23;92(10):1942-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells.
  • An understanding of the complexities of telomerase gene regulation in biologically heterogeneous leukaemia cells may offer new therapeutic approaches to the treatment of acute leukaemia.
  • [MeSH-major] Leukemia, Myeloid, Acute / enzymology. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Telomerase / analysis. Telomerase / pharmacology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. DNA-Binding Proteins. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Dec 2;402(6761):551-5 [10591218.001]
  • [Cites] Neoplasia. 2000 Sep-Oct;2(5):426-32 [11191109.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):593-8 [11179492.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):644-9 [11267974.001]
  • [Cites] Nature. 2001 Sep 27;413(6854):432-5 [11574891.001]
  • [Cites] Nucleic Acids Res. 2001 Dec 1;29(23):4818-25 [11726691.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):680-7 [11850796.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):688-97 [11850797.001]
  • [Cites] Lancet. 2002 Jun 22;359(9324):2168-70 [12090986.001]
  • [Cites] J Pathol. 2002 Sep;198(1):37-46 [12210061.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):257-65 [12398889.001]
  • [Cites] Lancet. 2003 Jun 7;361(9373):1993-4 [12801777.001]
  • [Cites] Blood. 2003 Aug 1;102(3):916-8 [12676774.001]
  • [Cites] Neoplasia. 2003 May-Jun;5(3):193-7 [12869302.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):6849-56 [12972604.001]
  • [Cites] Curr Med Res Opin. 2003;19(6):470-2 [14594517.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):127-31 [14654914.001]
  • [Cites] Nucleic Acids Res. 2004;32(1):371-9 [14729921.001]
  • [Cites] Science. 1995 Sep 1;269(5228):1236-41 [7544491.001]
  • [Cites] Science. 1997 Aug 15;277(5328):955-9 [9252327.001]
  • [Cites] Cell. 1997 Aug 22;90(4):785-95 [9288757.001]
  • [Cites] Hum Mol Genet. 1997 Nov;6(12):2011-9 [9328464.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6394-401 [9343401.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):498-502 [9398860.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4168-72 [9751630.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):619-25 [9815729.001]
  • [Cites] Gene. 1999 May 17;232(1):97-106 [10333526.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3936-42 [15319288.001]
  • (PMID = 15827550.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC2361762
  •  go-up   go-down


81. Dai D, Zhang SJ, Qiao C, Sun XM, Qian SX, Xu W, Xu YL, Li JY: [Analysis of NPM1 gene mutations in acute myeloid leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr;17(2):294-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of NPM1 gene mutations in acute myeloid leukemia].
  • The aim of this study was to evaluate the nucleophosmin (NPM1) gene exon 12 mutation in patients with acute myelogenous leukemia (AML) and its clinical characteristics.
  • Genomic DNAs from 33 AML patients were amplified by PCR and sequencing for NPM1 mutations.
  • The results showed that the NPM1 exon 12 mutations were found is 8 patients from 33 AML patients (24.2%) including 1 of M(1), 3 of M(2), 1 of M(4) and 3 of M(5).
  • It is concluded that the occurrence of NPM1 exon 12 mutations is observed more in AML patients with normal karyotype.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19379554.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin
  •  go-up   go-down


82. Crowley JA, Wang Y, Rapoport AP, Ning Y: Detection of MOZ-CBP fusion in acute myeloid leukemia with 8;16 translocation. Leukemia; 2005 Dec;19(12):2344-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of MOZ-CBP fusion in acute myeloid leukemia with 8;16 translocation.
  • [MeSH-major] Leukemia, Myeloid / genetics. Oncogene Proteins, Fusion / analysis
  • [MeSH-minor] Acute Disease. Adult. Bone Marrow. Chromosomes, Human, Pair 16. Chromosomes, Human, Pair 8. DNA Probes. Female. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Remission Induction / methods. Translocation, Genetic

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193081.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Probes; 0 / MOZ-CBP fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


83. Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA, van Besien K: Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant; 2005 May;35(10):965-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
  • The impact of disease burden on the outcome of patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation (SCT) has not been well defined.
  • Data from several retrospective series suggest that overt leukemia at the time of transplant increases the risk of relapse.
  • We reviewed the outcomes of 68 consecutive adults with AML (n=60) or myelodysplastic syndromes (MDS) (n=8) who received an allogeneic SCT at the University of Chicago between May 1986 and October 2002 to confirm the importance of currently recognized risk factors for overall survival (OS) and progression-free survival (PFS).
  • AML subtypes based on the FAB classification were as follows: M0=9, M1=9, M2=16, M3=2, M4=16, M5=3, M6=5.
  • Using standard morphologic criteria, 34 patients were in complete remission (CR) and 34 had visible leukemia present.
  • (1) increased percentage of blasts in the bone marrow at the time of SCT, (2) presence of acute graft-versus-host disease, (3) mismatched donor, (4) Zubrod performance score of >/=2, and (5) age >/=45 years.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy
  • [MeSH-minor] Adult. Aged. Cost of Illness. Female. Graft vs Host Disease / etiology. Histocompatibility Testing. Humans. Male. Middle Aged. Prognosis. Transplantation, Homologous


84. Wang XJ, Sun H, Wang GY, Fan QT: [Expression of anti-apoptosis livin gene in acute non-lymphocytic leukemia cells and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb;16(1):35-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of anti-apoptosis livin gene in acute non-lymphocytic leukemia cells and its clinical significance].
  • To explore the expression of livin gene in acute non-lymphocytic leukemia (ANLL) cells and its clinical significance, the mRNA level of livin gene in 46 ANLL adult patients were measured by using reverse transcription polymerase chain reaction (RT-PCR).
  • Other 10 healthy adults were selected as normal controls (NC), HL-60 cell line was employed as positive control.
  • The results showed that the mRNA level of livin gene in ANLL patients was significantly higher than that in NC, while it decreased in patients with complete remission (CR).
  • In ANLL patients, the CR rate of patients with livin positive was lower than that of patients with livin negative (p<0.05).
  • It is concluded that overexpression of livin gene may play a synergic role in the pathogenesis of ANLL and associates with CR rate in ANLL.
  • It seems that high expression of livin gene may be used as a marker of poor prognosis in acute non-lymphocytic leukemia.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18315896.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BIRC7 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


85. Cho BS, Choi HB, Kim HJ, Min WS, Kim CC, Kim TG: Typing by nested PCR-SSP approach raises a question about the feasibility of using this technique for detecting feto-maternal microchimerism. Leukemia; 2006 May;20(5):896-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] HLA Antigens / genetics. Leukemia, Myeloid / genetics. Polymerase Chain Reaction / methods. Transplantation Chimera / genetics
  • [MeSH-minor] Acute Disease. Adult. Child. Feasibility Studies. Female. Hematopoietic Stem Cell Transplantation / adverse effects. Histocompatibility Testing / methods. Humans. Male. Middle Aged. Recurrence. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498389.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


86. Kokhno AV, Parovichnikova EN, Mikhaĭlova EA, Ustinova EN, Kaplanskaia IB, Dvirnyk VN, Ol'shanskaia IuV, Domracheva EV, Savchenko VG: [Efficiency of cyclosporin A therapy in patients with myelodysplastic syndrome]. Ter Arkh; 2010;82(8):48-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Baseline refractory anemia (RA) transformed to RA with excess blasts (RAEB) in 31% of cases; baseline RAEB did to acute myeloid leukemia in 34%.
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow / pathology. Chromosome Aberrations. Dose-Response Relationship, Drug. Female. Humans. Kaplan-Meier Estimate. Karyotyping. Male. Middle Aged. Prognosis. Young Adult


87. Nakamura S, Hirano I, Okinaka K, Takemura T, Yokota D, Ono T, Shigeno K, Shibata K, Fujisawa S, Ohnishi K: The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. Carcinogenesis; 2010 Nov;31(11):2012-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia.
  • However, it is not clearly understood how FOXM1 contributes to acute myeloid leukemia (AML) cell proliferation.
  • In this study, we investigated the cellular and molecular function of FOXM1 in AML cells.
  • The FOXM1 messenger RNA (mRNA) expressed in AML cell lines was predominantly the FOXM1B isoform, and its levels were significantly higher than in normal high aldehyde dehydrogenase activity (ALDH(hi)) cells.
  • Reduction of FOXM1 expression in AML cells inhibited cell proliferation compared with control cells, through induction of G(2)/M cell cycle arrest, a decrease in the protein expression of Aurora kinase B, Survivin, Cyclin B1, S-phase kinase-associated protein 2 and Cdc25B and an increase in the protein expression of p21(Cip1) and p27(Kip1).
  • FOXM1 messenger RNA (mRNA) was overexpressed in all 127 AML clinical specimens tested (n = 21, 56, 32 and 18 for M1, M2, M4 and M5 subtypes, respectively).
  • Compared with normal ALDH(hi) cells, FOXM1 gene expression was 1.65- to 2.26-fold higher in AML cells.
  • Moreover, the FOXM1 protein was more strongly expressed in AML-derived ALDH(hi) cells compared with normal ALDH(hi) cells.
  • In addition, depletion of FOXM1 reduced colony formation of AML-derived ALDH(hi) cells due to inhibition of Cdc25B and Cyclin B1 expression.
  • In summary, we found that FOXM1B mRNA is predominantly expressed in AML cells and that aberrant expression of FOXM1 induces AML cell proliferation through modulation of cell cycle progression.
  • Thus, inhibition of FOXM1 expression represents an attractive target for AML therapy.
  • [MeSH-major] Cell Cycle. Cell Cycle Proteins / metabolism. Cell Proliferation. Forkhead Transcription Factors / physiology. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Adult. Aged. Aldehyde Dehydrogenase / genetics. Aldehyde Dehydrogenase / metabolism. Apoptosis. Aurora Kinase B. Aurora Kinases. Blotting, Western. Cells, Cultured. Cyclin B1 / genetics. Cyclin B1 / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cyclin-Dependent Kinase Inhibitor p27. Disease Progression. Fluorescent Antibody Technique. Humans. Inhibitor of Apoptosis Proteins. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Lymphocytes / metabolism. Microtubule-Associated Proteins / genetics. Microtubule-Associated Proteins / metabolism. Middle Aged. Protein-Serine-Threonine Kinases / genetics. Protein-Serine-Threonine Kinases / metabolism. RNA, Messenger / genetics. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. S-Phase Kinase-Associated Proteins / genetics. S-Phase Kinase-Associated Proteins / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20823107.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / CCNB1 protein, human; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin B1; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / FOXM1 protein, human; 0 / Forkhead Transcription Factors; 0 / Inhibitor of Apoptosis Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Microtubule-Associated Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / S-Phase Kinase-Associated Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 1.2.1.3 / Aldehyde Dehydrogenase; EC 2.7.11.1 / AURKB protein, human; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


88. Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J: Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol; 2008 Apr;61(5):759-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
  • PURPOSE: In this study, pharmacokinetics (PK) of decitabine administered as a 3-h intravenous infusion of 15 mg/m2 every 8 h for 3 days (cycles repeated every 6 weeks) was evaluated in patients with MDS or AML.
  • METHODS: The PK of this dosing regimen was evaluated in sixteen patients with MDS or AML.
  • CONCLUSIONS: Decitabine dosed at 15 mg/m2 iv every 8 h for 3 days resulted in a predictable and manageable toxicity profile in patients with MDS/AML.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacokinetics. Azacitidine / analogs & derivatives. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Bone Marrow / drug effects. Bone Marrow / pathology. Chromatography, High Pressure Liquid. Drug Administration Schedule. Female. Half-Life. Humans. Infusions, Intravenous. Male. Mass Spectrometry. Middle Aged. Sepsis / etiology. Tissue Distribution


89. Kara IO, Sahin B, Paydas S, Kara B: Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone. Leuk Lymphoma; 2005 Jul;46(7):1081-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone.
  • We present a case of granulocytic sarcoma (GS) of the heart.
  • A 28-year-old man with relapsed acute myelogenous leukemia (AML-M2) had undergone a non-myeloablative allogeneic peripheral stem cell transplantation.
  • Three years following transplantation, masses were evidenced in his heart by echocardiography but had completely disappeared following a common chemotherapy etoposide, mitoxantrone, ara-C (EMA) regimen for relapsed AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation / adverse effects. Sarcoma, Myeloid / drug therapy. Sarcoma, Myeloid / etiology
  • [MeSH-minor] Adult. Cytarabine / administration & dosage. Etoposide / administration & dosage. Heart Neoplasms / diagnosis. Heart Neoplasms / drug therapy. Heart Neoplasms / etiology. Humans. Male. Mitoxantrone / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Remission Induction. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019562.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


90. Middeldorf I, Galm O, Osieka R, Jost E, Herman JG, Wilop S: Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML). Am J Hematol; 2010 Jul;85(7):477-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML).
  • In older patients suffering from acute myelogenous leukemia (AML), aggressive chemotherapy is accompanied with high treatment-related morbidity and mortality.
  • Consequently, a variable response of AML cells to anti-CD33-targeted therapy may be caused by modulation of SOCS3 expression.
  • Twenty-four patients with refractory or relapsed CD33-positive AML received GO as a single agent before or after conventional chemotherapy.
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. DNA Methylation. Leukemia, Myeloid, Acute / drug therapy. Salvage Therapy / methods. Suppressor of Cytokine Signaling Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. CpG Islands. Drug Administration Schedule. Humans. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20575043.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / SOCS3 protein, human; 0 / Suppressor of Cytokine Signaling Proteins; 0 / gemtuzumab
  •  go-up   go-down


91. Estey E, Döhner H: Acute myeloid leukaemia. Lancet; 2006 Nov 25;368(9550):1894-907
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukaemia.
  • Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haemopoietic progenitor cells and the most common malignant myeloid disorder in adults.
  • The median age at presentation for patients with AML is 70 years.
  • Whereas significant progress has been made in the treatment of younger adults, the prospects for elderly patients have remained dismal, with median survival times of only a few months.
  • [MeSH-major] Leukemia, Myeloid. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2007 Feb 3;369(9559):367 [17276770.001]
  • (PMID = 17126723.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 178
  •  go-up   go-down


92. Marisavljevic D, Kraguljac-Kurtovic N: Biological implications of circulating CD34(+) cells in myelodysplastic syndromes. J BUON; 2010 Oct-Dec;15(4):753-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD34(+) status was correlated with the percentage of circulating and bone marrow blasts, cytogenetic studies, CFU-GM colony growth, overall survival and transformation to acute myeloid leukemia (AML).
  • Five patients with elevated proportion of circulating CD34(+) cells progressed to AML, as compared to only one of CD34(-)negative (CD34(-)) cases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow / immunology. Bone Marrow / metabolism. Case-Control Studies. Colony-Forming Units Assay. Female. Flow Cytometry. Humans. Immunophenotyping. Karyotyping. Male. Middle Aged. Myeloid Cells / metabolism. Prognosis. Survival Rate


93. Lu Y, Chen W, Chen W, Stein A, Weiss LM, Huang Q: C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics. Am J Hematol; 2010 Jun;85(6):426-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics.
  • In the current study, we investigated C/EBPA gene mutations and promoter hypermethylation in a series of 53 patients with CN-AML.
  • Interestingly, they were all in CN-AML cases without FLT3/ITD or NPM1 mutations.
  • In conclusion, C/EBPA mutation and promoter hypermethylation can be detected at a relatively low frequency in de novo CN-AML patients, suggesting they may contribute to leukemogenesis.
  • C/EBPA mutation appears to be seen in "high-risk" AML (FLT3/ITD+/NPM1+; FLT3/ITD+/NPM1- or FLT3/ITD-/NPM1-), while C/EBPA hypermethylation appears to be more common in AML with FLT3/ITD- /NPM1- and is not associated with C/EBPA mutation.
  • [MeSH-major] CCAAT-Enhancer-Binding Proteins / genetics. DNA Methylation. Leukemia, Myeloid / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Cell Transformation, Neoplastic / genetics. DNA Mutational Analysis. Female. Humans. Male. Middle Aged. Nuclear Proteins / genetics. Risk. Young Adult. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20513120.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Proteins; 0 / CEBPA protein, human; 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


94. Rodriguez CP, Baz R, Jawde RA, Rybicki LA, Kalaycio ME, Advani A, Sobecks R, Sekeres MA: Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia. Leuk Res; 2008 Mar;32(3):413-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia.
  • BACKGROUND: While socioeconomic status (SES) and the distance patients travel to a treatment center (DTC) impact survival of certain solid tumors, little is known of their influence in acute myeloid leukemia (AML).
  • METHODS: We retrospectively reviewed patients receiving remission induction therapy for AML at the Cleveland Clinic between January 1997 and December 2005.
  • Known prognostic factors (age, WBC count at diagnosis, cytogenetics, AML etiology) were collected and controlled for in Cox proportional hazards analysis.
  • RESULTS: Induction chemotherapy was administered to 281 patients; 91% were Caucasian (C), 8% were African American (AA), and 1% were neither (non-AA non-C).
  • In multivariable analyses, age >or=60 years, unfavorable cytogenetics, initial WBC count and secondary AML significantly influenced survival (p<0.001, p<0.001, p=0.035, and p=0.010, respectively).
  • OS was similar for AAs and non-AA non-Cs compared to Cs (HR=1.12, 95% CI=.61-2.07, p=.71, and HR=0.87, CI=0.21-3.62, p=.84, respectively).
  • CONCLUSION: Unlike with many solid tumors, SES and DTC are not predictive of outcome in AML patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / psychology. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Continental Population Groups. Female. Follow-Up Studies. Health Services Accessibility. Humans. Male. Middle Aged. Remission Induction. Social Class. Survival Analysis. Treatment Outcome


95. Harrison CJ, Griffiths M, Moorman F, Schnittger S, Cayuela JM, Shurtleff S, Gottardi E, Mitterbauer G, Colomer D, Delabesse E, Castéras V, Maroc N: A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device. Cancer Genet Cytogenet; 2007 Feb;173(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device.
  • Rearrangements of the MLL gene are significant in acute leukemia.
  • Among the most frequent translocations are t(4;11)(q21;q23) and t(9;11)(p22;q23), which give rise to the MLL-AFF1 and MLL-MLLT3 fusion genes (alias MLL-AF4 and MLL-AF9) in acute lymphoblastic and acute myeloid leukemia, respectively.
  • Current evidence suggests that determining the MLL status of acute leukemia, including precise identification of the partner gene, is important in defining appropriate treatment.
  • A novel molecular diagnostic device, the MLL FusionChip, has been successfully used to identify MLL fusion gene translocations in acute leukemia, including the precise breakpoint location.
  • [MeSH-major] Leukemia, Myeloid / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Adult. Child. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 4. Chromosomes, Human, Pair 9. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. Infant. Oligonucleotide Array Sequence Analysis / instrumentation. Oligonucleotide Array Sequence Analysis / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Genet Cytogenet. 2007 Dec;179(2):167
  • (PMID = 17284365.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / MLL-AF4 fusion protein, human; 0 / MLL-AF9 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / RNA, Neoplasm; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


96. Tanaka-Harada Y, Kawakami M, Oka Y, Tsuboi A, Katagiri T, Elisseeva OA, Nishida S, Shirakata T, Hosen N, Fujiki F, Murao A, Nakajima H, Oji Y, Kanda Y, Kawase I, Sugiyama H: Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies. Cancer Sci; 2010 Mar;101(3):594-600
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.
  • WT1 (Wilms' tumor gene 1) protein is a potent pan-tumor-associated antigen (TAA) and WT1-specific cytotoxic T lymphocytes (WT1 tetramer(+) CD8(+) T cells) are spontaneously induced in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
  • We conducted a single-cell level comparative analysis of T-cell receptor beta-chain variable region (TCR-BV) gene families of a total of 1242 spontaneously induced WT1 tetramer(+) CD8(+) T cells in HLA-A*2402(+) patients with AML or MDS and those in healthy donors (HDs).
  • (iii) that BV19 was commonly biased in the patients; and (iv) that BVs 7 and 28, BVs 9 and 15, and BVs 12 and 29 were specifically biased in HDs, AML, and MDS patients, respectively.
  • However, statistical analysis of similarity among HD, AML, and MDS of individual usage frequencies of 24 kinds of TCR-BV gene families indicated that the usage frequencies of TCR-BV gene families in AML and MDS patients reflect those in HDs.
  • [MeSH-major] CD8-Positive T-Lymphocytes / immunology. Genes, T-Cell Receptor beta. Leukemia, Myeloid, Acute / immunology. Myelodysplastic Syndromes / immunology. WT1 Proteins / immunology
  • [MeSH-minor] Adult. Aged. Antigens, CD45 / analysis. Female. Humans. Male. Middle Aged. Receptors, CCR7 / analysis


97. Horikoshi A, Takei K, Hosokawa Y, Sawada S: The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients. Int J Hematol; 2008 Mar;87(2):118-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients.
  • Twenty-one acute myeloid leukemia (AML) patients were enrolled and received oral induction therapy with cytarabine ocfosfate (SPAC) and etoposide (EP).
  • There were 11 patients with de novo AML and 10 AML cases that had evolved from myelodysplastic syndromes.
  • We conclude that this therapy is well tolerated and useful for refractory and elderly AML patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Arabinonucleotides / administration & dosage. Arabinonucleotides / adverse effects. Arabinonucleotides / blood. Cytidine Monophosphate / administration & dosage. Cytidine Monophosphate / adverse effects. Cytidine Monophosphate / analogs & derivatives. Cytidine Monophosphate / blood. Etoposide / administration & dosage. Etoposide / adverse effects. Etoposide / blood. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 1989 Jul;80(7):679-85 [2507491.001]
  • [Cites] Blood. 1987 Jun;69(6):1551-62 [3555647.001]
  • [Cites] Cancer Treat Rep. 1984 Nov;68(11):1357-66 [6498853.001]
  • [Cites] Cancer Res. 1985 Dec;45(12 Pt 1):6498-501 [3864533.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Dec;24(12):1823-8 [3220079.001]
  • [Cites] Leuk Res. 1983;7(4):539-45 [6578393.001]
  • [Cites] Oncology. 1991;48(6):451-5 [1749580.001]
  • [Cites] Cancer Invest. 1993;11(4):388-92 [8324643.001]
  • [Cites] Br J Haematol. 1993 Jan;83(1):1-6 [7679585.001]
  • [Cites] Leuk Lymphoma. 2001 Jul;42(3):347-55 [11699399.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1340-6 [12663724.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Jpn J Cancer Res. 1991 Feb;82(2):184-91 [1848545.001]
  • [Cites] Eur J Cancer. 1975 Sep;11(9):639-47 [1220978.001]
  • [Cites] Haematologica. 2004 Apr;89(4):408-18 [15075074.001]
  • [Cites] Biomed Pharmacother. 1990;44(2):93-101 [2224060.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):896-903 [8078551.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2646-54 [15994288.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300 [9732391.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1798-803 [15385923.001]
  • [Cites] Gan To Kagaku Ryoho. 1990 Dec;17(12):2387-95 [2260876.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):422-6 [8697386.001]
  • [Cites] Br J Haematol. 1992 Oct;82(2):354-7 [1419818.001]
  • [Cites] Br J Haematol. 1982 May;51(1):125-9 [6951603.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):109-13 [8261429.001]
  • [Cites] Haematologica. 1987 Jul-Aug;72(4):341-5 [3117635.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2952-61 [9376575.001]
  • [Cites] Leukemia. 2000 Mar;14(3):476-9 [10720145.001]
  • [Cites] Int J Hematol. 1997 Apr;65(3):263-8 [9114597.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2908-13 [15070662.001]
  • [Cites] Leuk Res. 2005 Mar;29(3):263-71 [15661261.001]
  • [Cites] Gan To Kagaku Ryoho. 1990 Nov;17(11):2213-9 [2241185.001]
  • (PMID = 18228114.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Arabinonucleotides; 3I7U8R8NWC / 1-arabinofuranosylcytosine-5'-stearylphosphate; 6PLQ3CP4P3 / Etoposide; F469818O25 / Cytidine Monophosphate
  •  go-up   go-down


98. Hess EP, Sztajnkrycer MD: Images in emergency medicine. Acute leukemia with blast crisis, disseminated intravascular coagulation, and intraparenchymal hemorrhage. Ann Emerg Med; 2005 Oct;46(4):314, 322
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in emergency medicine. Acute leukemia with blast crisis, disseminated intravascular coagulation, and intraparenchymal hemorrhage.
  • [MeSH-major] Cerebral Hemorrhage / etiology. Disseminated Intravascular Coagulation / etiology. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / radiography. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiography
  • [MeSH-minor] Adult. Blast Crisis. Diagnosis, Differential. Fatal Outcome. Fibrin Fibrinogen Degradation Products / analysis. Headache / etiology. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16187462.001).
  • [ISSN] 1097-6760
  • [Journal-full-title] Annals of emergency medicine
  • [ISO-abbreviation] Ann Emerg Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrin Fibrinogen Degradation Products; 0 / fibrin fragment D
  •  go-up   go-down


99. Wang YL, Wang T, Xu F, Gang Y, Wang J: [Analysis of DEK-CAN fusion gene expression in acute myeloid leukemia patients with 6; 9 chromosome translocation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr;14(2):232-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of DEK-CAN fusion gene expression in acute myeloid leukemia patients with 6; 9 chromosome translocation].
  • This study was aimed to explore the relationship of 6; 9 chromosome translocation with DEK-CAN fusion gene expression in patients with acute myeloid leukemia (AML) and its clinical significance.
  • Chromosome specimens were prepared by routine method after short-term culture of bone marrow cells; karyotype analysis was performed by R banding technique; the expression of fusion gene DEK-CAN was analyzed by RT-nested-PCR in mononuclear cells of bone marrow or peripheral blood of 4 AML patients, for 3 patients received allo-BMT out of 4 patients the dynamic follow-up was performed.
  • q34) was confirmed by chromosome karyotype analysis in the four AML patients.
  • It is concluded that DEK-CAN fusion gene is the molecular basis in pathogenesis of AML.
  • The detection of DEK-CAN fusion gene is significant for diagnosis of AML, evaluation of curative effect, and predication of prognosis.

  • Genetic Alliance. consumer health - Chromosome 9.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638187.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DEK-CAN fusion protein, recombinant; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


100. Graef T, Vaupel M, Fenk R, Ruf L, Zohren F, Germing U, Haas R, Kobbe G: Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation. Hematol Oncol; 2007 Dec;25(4):170-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation.
  • In this uni-centre retrospective study, we studied 120 adults with acute myeloid leukaemia (AML) (n = 88) and myelodysplastic syndrome (MDS) (n = 32) who received first allogeneic HSCT to determine prognostic factors which are correlated with the outcome after myeloablative (MA) or non-myeloablative (non-MA) allogeneic HSCT.
  • A total of 97 patients received a MA regimen and 23 were treated with a non-MA regimen.
  • Three-year probabilities of non-relapse mortality (34 vs. 54%; p = 0.9) did not differ in the MA and non-MA groups, but differences were observed in the disease-free survival (DFS) (43 vs. 17%; p = 0.1) and the relapse rate (RR) (29 vs. 62%; p = 0.01).
  • In this study, the clinical benefit of a lower toxicity regimen was offset by higher RR resulting in inferior results in the non-MA group, especially when no CR was achieved by prior induction or salvage therapy.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Chromosome Aberrations. Female. Graft vs Host Disease. Humans. Male. Middle Aged. Myelodysplastic Syndromes. Prognosis. Proportional Hazards Models. Recurrence. Remission Induction. Retrospective Studies. Transplantation, Homologous. Treatment Outcome






Advertisement